Icagen 10-Q 14 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 14, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Caldera Pharmaceuticals Inc	'
Entity Central Index Key	'0001518520	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	4,197,270

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash	$1,009,701	$378,643
Accounts receivable, net	66,712	59,849
Prepaid expenses	67,674	17,055
Total current assets	1,144,087	455,547
Non-current assets:	'	'
Intangible assets, net	555,811	594,574
Plant and equipment, net	411,079	391,530
Investment in certificate of deposit	25,000	'
Total non-current assets	991,890	986,104
TOTAL ASSETS	2,135,977	1,441,651
Current liabilities:	'	'
Accounts payable	528,430	374,048
Other payables and accrued expenses	282,140	197,307
Loans payable	115,671	218,324
Bridge notes payable, net of debt discount	'	233,955
Derivative financial liability	1,475,975	17,539
Dividends payable	242,374	156,873
Total current liabilities	2,644,590	1,198,046
Non-current liabilities:	'	'
Loans payable	370,306	332,055
Other payables and accrued expenses	82,800	160,000
Total non-current liabilities	453,106	492,055
TOTAL LIABILITIES	3,097,696	1,690,101
Convertible Redeemable Preferred Stock	'	'
Series A Cumulative Convertible Redeemable Preferred Stock, $0.001 par value, 400,000 shares designated, 105,000 and 341,607 shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively, liquidation preference is $5.70 per share.	133,350	2,065,392
Commitments and contingencies	'	'
STOCKHOLDERS' DEFICIT:	'	'
Preferred stock, $0.001 par value, 10,000,000 authorized shares, 6,600,000 shares undesignated and unissued.	'	'
Series B Cumulative Convertible Preferred Stock, $0.001 par value, 3,000,000 designated shares, and 2,133,947 shares issued and outstanding as of September 30, 2013, liquidation preference is $2.50 per share.	5,167,810	'
Common stock, $0.001 par value, 50,000,000 authorized shares, 4,851,270 and 4,956,270 shares issued and, 4,197,270 and 4,302,270 outstanding as of September 30, 2013 and December 31, 2012, respectively.	4,851	4,957
Additional paid in capital	5,090,675	4,649,109
Treasury stock, at cost, 654,000 shares of common stock as of September 30, 2013 and December 31, 2012	-473	-473
Accumulated deficit	-11,357,932	-6,967,435
Total stockholders' deficit	-1,095,069	-2,313,842
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$2,135,977	$1,441,651

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Preferred stock, par value	$0.00	$0.00
Preferred Stock undesignated and unissued shares	6,600,000	6,600,000
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	4,851,270	4,956,270
Common stock, shares outstanding	4,197,270	4,302,270
Treasury stock, shares	654,000	654,000
Series A Preferred Stock	'	'
Convertible redeemable preferred stock, par value	$0.00	$0.00
Convertible redeemable preferred stock, shares designated	400,000	400,000
Convertible redeemable preferred stock, shares issued	105,000	341,607
Convertible redeemable preferred stock, shares outstanding	105,000	341,607
Convertible redeemable preferred stock, liquidation preference per share	$5.70	$5.70
Series B Preferred Stock	'	'
Convertible redeemable preferred stock, par value	$0.00	'
Preferred Stock, Shares Authorized	3,000,000	3,000,000
Convertible redeemable preferred stock, shares designated	3,000,000	'
Convertible redeemable preferred stock, shares issued	2,133,947	'
Convertible redeemable preferred stock, shares outstanding	2,133,947	'
Convertible redeemable preferred stock, liquidation preference per share	$2.50	'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Statements of Operations [Abstract]	'	'	'	'
Sales	$60,628	$582,925	$380,923	$1,453,950
Cost of sales	101,119	151,968	372,843	504,092
Gross (loss)/profit	-40,491	430,957	8,080	949,858
Operating expenses:	'	'	'	'
Selling, general and administrative expenses	976,848	308,934	2,466,838	1,384,972
Depreciation	30,704	27,009	86,353	66,033
Amortization	12,921	12,921	38,763	38,763
Total operating expenses	1,020,473	348,864	2,591,954	1,489,768
Operating (loss)/profit	-1,060,964	82,093	-2,583,874	-539,910
Other income/(expense)	'	'	'	'
Other income	'	140,880	'	140,880
Interest income	458	141	1,142	635
Interest expense	-16,267	-7,306	-155,968	-15,144
Change in fair value of derivative liabilities	536,665	'	388,094	'
Total other income	520,856	133,715	233,268	126,371
Net (loss)/profit	-540,108	215,808	-2,350,606	-413,539
Deemed preferred stock dividends	-16,925	'	-1,745,837	-2,857
Preferred stock dividends	-146,470	-39,499	-294,054	-117,373
Net (loss)/profit applicable to common stock	($703,503)	$176,309	($4,390,497)	($533,769)
Net loss per common stock: -	'	'	'	'
Basic	($0.17)	$0.04	($1.03)	($0.12)
Diluted	($0.17)	$0.04	($1.03)	($0.12)
Weighted average number of common stock outstanding: -	'	'	'	'
Basic	4,197,270	4,302,270	4,251,116	4,297,848
Diluted	4,197,270	4,310,225	4,251,116	4,297,848

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flow from operating activities	'	'
Net loss	($2,350,606)	($413,539)
Adjustments for non-cash items:	'	'
Depreciation	86,353	66,033
Amortization	38,763	38,763
Amortization of bridge note discount	117,629	'
Stock based compensation payments	441,566	48,852
Loss on plant and equipment scrapped	1,082	'
Increase in receivables provision	14,086	'
Decrease in fair value of derivative financial liability	-388,094	'
Increase in legal settlement accrual	115,273	'
Gain on settlement reached with supplier	'	-130,880
Changes in operating assets and liabilities:	'	'
Increase in accounts receivable	-20,949	-72,043
Increase in prepaid expenses	-50,619	-21,154
Increase/(decrease) in accounts payable	154,382	-89,332
Increase in other payables and accrued expenses	33,190	8,143
Net cash used in operating activities	-1,807,944	-565,157
Cash flow from investing activities	'	'
Purchase of plant and equipment	-106,984	-238,360
Investment in certificate of deposit	-25,000	'
Net cash used in investing activities	-131,984	-238,360
Cash flow from financing activities	'	'
Advance on term loan	267,392	'
Advance on line of credit	'	168,000
Advance on commercial loan	'	148,500
Advance on Bridge loans	250,000	'
Repayment of Los Alamos County loan	-23,274	-22,152
Repayment of line of credit	-168,000	'
Repayment of commercial loan	-139,832	-4,331
Repayment of Bridge loans	-125,000	'
Proceeds of Series A Preferred stock issued	'	57,500
Proceeds on Series B Preferred stock issued, net of issue expenses	2,509,700	'
Preferred stock dividends paid	'	-26,752
Net cash provided by financing activities	2,570,986	320,765
Net increase/(decrease) in cash	631,058	-482,752
Cash at the beginning of the period	378,643	678,300
Cash at the end of the period	1,009,701	195,548
Cash paid for:	'	'
Interest	30,752	13,800
Income taxes	'	'
Non-cash investing and financing activities:	'	'
Common stock issued in lieu of preferred stock dividends	'	60,705
Series B Preferred stock issued in exchange for Series A Preferred stock	2,065,392	'
Series B Preferred stock issued in lieu of series A Preferred stock dividends	208,558	'
Series B Preferred stock issued upon conversion of Bridge notes and interest thereon	384,160	'
Deemed preferred stock dividends relating to warrants issued to preferred stock holders	$1,745,837	$2,857

General_Information

General Information	9 Months Ended
	Sep. 30, 2013
General Information [Abstract]	'
GENERAL INFORMATION	'
	1.	GENERAL INFORMATION
	Caldera Pharmaceuticals, Inc. (“the Company”, “we”, “us”, “our”) is a Delaware corporation. The principal office was relocated from Los Alamos, New Mexico to Cambridge, Massachusetts during June 2013. The Company was incorporated in November 2003.
	The Company uses proprietary x-ray fluorescence technology called XRpro® to deliver ion channel screening, ion channel kinetics and custom screening services to our customers. Our proprietary technology detects and quantitatively analyzes the x-ray signature of each element with an atomic number greater than 10, we combine the flexibility of the analysis with patented sample processing to address a wide range of ion channel and other biological targets.
	The Company has generated the majority of its revenues to date through Government research contracts and Government grants utilizing its proprietary x-ray fluorescence technology.

Accounting_Policies_and_Estima

Accounting Policies and Estimates

9 Months Ended

Sep. 30, 2013

Accounting Policies and Estimates [Abstract]

'

ACCOUNTING POLICIES AND ESTIMATES

'

2.

ACCOUNTING POLICIES AND ESTIMATES

Basis of Presentation

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

In the opinion of management, all adjustments necessary to fairly present the results for the interim periods presented have been made. All adjustments made are of a normal and recurring nature and no non-recurring adjustments have been made in the presentation of these interim financial statements.

All amounts referred to in the notes to the financial statements are in United States Dollars ($) unless stated otherwise.

Consolidation

The consolidated financial statements include the financial statements of the Company and its subsidiaries in which it has a majority voting interest. Investments in affiliates are accounted for under the cost method of accounting, where appropriate. All significant inter-company accounts and transactions have been eliminated in the consolidated financial statements. The entities included in these consolidated financial statements are as follows:

Caldera Pharmaceuticals, Inc. - Parent Company

XRpro Corp. – Wholly owned subsidiary

Estimates

The preparation of these financial statements in accordance with US GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to bad debts and recovery of long-lived assets. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the allowance for doubtful accounts, the useful life of plant and equipment and intangible assets, and assumptions used in assessing impairment of long-term assets and the assumptions used in determining percentage of completion on our long-term contracts.

Contingencies

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

Fair value of financial instruments

The Company adopted the guidance of Accounting Standards Codification (“ASC”) 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:

Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.

Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other then quoted prices that are observable, and inputs derived from or corroborated by observable market data.

Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.

The carrying amounts reported in the balance sheets for cash, accounts receivable, loans payable, accounts payable and accrued expenses approximate their fair market value based on the short-term maturity of these instruments. The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with the accounting guidance.

ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

Reporting by segment

No segmental information is presented as the Company only has one significant reporting segment that is Government Revenues.

Intangible assets

All of our intangible assets are subject to amortization. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. Where intangibles are deemed to be impaired we recognize an impairment loss measured as the difference between the estimated fair value of the intangible and its book value.

a)    License Agreements

License agreements acquired by the Company are reported at acquisition value less accumulated amortization and impairments.

b)    Amortization

Amortization is reported in the income statement on a straight-line basis over the estimated useful life of the intangible assets, unless the useful life is indefinite. Amortizable intangible assets are amortized from the date that they are available for use. The estimated useful life of the license agreement is twenty years which is the term of the patent supporting the underlying license agreements

Plant and equipment

Plant and equipment is stated at cost less accumulated depreciation.  Depreciation is computed using straight-line method over the estimated useful lives of the assets. The estimated useful lives of the assets are as follows:

Leasehold improvements

5 Years

Laboratory equipment

7 Years

Furniture and fixtures

10 Years

Computer equipment

3 Years

Motor vehicles (used)

2 Years

The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition.

We examine the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. We recognize an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.

Concentrations of credit risk

The Company’s operations are carried out in the USA. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in the USA and by the general state of the economy. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, and rates and methods of taxation, among other things.

Concentration of major customers

The Company currently derives substantially all of its revenues from Government research contracts and Government grants.

These Government research contracts are primarily from two government agencies: The Department of Defense and the National Institutes of Health. The granting of research contracts from Government agencies is a competitive process and there is no certainty that we will be awarded future contracts, which may cause our revenue to fluctuate from year to year. Furthermore, Government grants are subject to audits by the granting agency. If such audits were to determine that expenditures of the grant funds did not meet the applicable criteria, these amounts could be subject to retroactive adjustment and refunded to the granting agency.

Total revenues by customer type are as follows:

$

Three months

Three months

Nine months

Nine months

ended

ended

ended

ended

September 30,

September 30,

September 30,

September 30,

2013

2012

2013

2012

National Institutes of Health

$

60,628

$

552,708

313,805

$

1,423,733

Department of Defense

-

16,925

67,118

16,925

Commercial customers

-

13,292

-

13,292

$

60,628

$

582,925

$

380,923

$

1,453,950

Accounts receivable and other receivables

We have a policy of reserving for uncollectible accounts based on our best estimate of the amount of probable credit losses in our existing accounts receivable. As a basis for accurately estimating the likelihood of collection of our accounts receivable, we consider a number of factors when determining reserves for uncollectable accounts. We believe that we use a reasonably reliable methodology to estimate the collectability of our accounts receivable. We review our allowances for doubtful accounts on a regular basis. We also consider whether the historical economic conditions are comparable to current economic conditions. If the financial condition of our customers or other parties that we have business relations with were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.

The balance of the receivables provision as at September 30, 2013 and December 31, 2012 was $14,086 and $0, respectively. The amount charged to bad debt provision for the nine months ended September 30, 2013 and 2012 was $14,086 and $0, respectively.

Cash and cash equivalents

For purposes of the statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents. The Company maintains cash and cash equivalents with two financial institutions in the USA.

Revenue recognition

Revenue sources consist of government grants, government contracts and commercial development contracts.

We account for our long-term Firm Fixed Price Government contracts and grants associated with the delivery of research on drug candidates and the development of drug candidates using the percentage-of-completion accounting method. Under this method, revenue is recognized based on the extent of progress towards completion of the long-term contract.

We generally use the cost-to-cost measure of progress for all of our long-term contracts, unless we believe another measure will produce a more reliable result. We believe that the cost-to-cost measure is the best and most reliable performance indicator of progress on our long-term contracts as all our contract estimates are based on costs that we expect to incur in performing our long-term contracts and we have not experienced any significant variations on estimated to actual costs to date. Under the cost-to-cost measure of progress, the extent of progress towards completion is based on the ratio of costs incurred-to-date to the total estimated costs at the completion of the long-term contract. Revenues, including estimated fees or profits are recorded as costs are incurred.

When estimates of total costs to be incurred on a contract exceed total estimates of revenue to be earned, a provision for the entire loss on the contract is recorded in the period the loss is determined.

To a much lesser extent, we enter into fixed fee commercial development contracts that are not associated with the delivery of feasible research on drug candidates and the development of drug candidates. Revenue under such contracts is generally recognized upon delivery or as the development is performed.

Sales and Marketing

Sales and marketing expenses are minimal at present. These costs, if any, are expensed as incurred and included in Selling, general and administrative expenses. The Company expects to incur sales and marketing expenses in future periods to promote its services to drug discovery enterprises.

Research and Development

The remuneration of the Company’s research and development staff, materials used in internal research and development activities, and payments made to third parties in connection with collaborative research and development arrangements, are all expensed as incurred.  Where the Company makes a payment to a third party to acquire the right to use a product formula which has received regulatory approval, the payment is accounted for as the acquisition of a license or patent and is capitalized as an intangible asset and amortized over the shorter of the license period or the patent life.

The amount expensed for unrecovered research costs, included in Selling, general and administrative expenses during the three months and the nine months ended September 30, 2013 was $46,944 and $122,347, respectively.

Patent Costs

Legal costs in connection with approved patents and patent applications are expensed as incurred and classified as Selling, general and administrative expense in our consolidated statement of operations.

Share-Based Compensation

Share-based compensation cost is measured at the grant date, based on the estimated fair value of the award and is recognized as expense over the employee's requisite service period or vesting period on a straight-line basis. Share-based compensation expense recognized in the consolidated statements of operations for the nine months ended September 30, 2013 and 2012 is based on awards ultimately expected to vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. We have no awards with market or performance conditions.

Income Taxes

The Company utilizes ASC 740, Accounting for Income Taxes, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

Net loss per Share

Basic net loss per share is computed on the basis of the weighted average number of common stock outstanding during the period.

Diluted net loss per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation.

Dilution is computed by applying the treasury stock method for options and warrants. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.

Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share).

Comprehensive income

Comprehensive income is defined as the change in equity of a company during a period from transactions and other events and circumstances excluding transactions resulting from investments from owners and distributions to owners. For the Company, comprehensive income for the periods presented includes net income/(loss).

Related parties

Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company shall disclose all related party transactions. All transactions shall be recorded at fair value of the goods or services exchanged. Property purchased from a related party is recorded at the cost to the related party and any payment to or on behalf of the related party in excess of the cost is reflected as a distribution to related party.

Reclassification

Certain reclassifications have been made to conform the prior period data to the current presentation. These reclassifications have no effect on reported net loss.

Recent accounting pronouncements

The Company has reviewed all recently issued, nut not yet effective, accounting pronouncements and does not expect the future adoption of any such pronouncements to have a significant impact on the results of operations, financial condition or cash flow.

Going_Concern

Going Concern	9 Months Ended
	Sep. 30, 2013
Going Concern [Abstract]	'
GOING CONCERN	'
	3.	GOING CONCERN
	As shown in the accompanying unaudited consolidated financial statements, the Company incurred a net loss of $2,350,606 and $413,539 during the nine months ended September 30, 2013 and 2012, respectively. As of September 30, 2013, the Company had an accumulated deficit of $11,357,932. The Company had a working capital deficiency of $1,500,503, including a non-cash derivative liability of $1,475,975 as of September 30, 2013. These operating losses and working capital deficiency create an uncertainty about the Company’s ability to continue as a going concern. Although no assurances can be given, management of the Company believes that potential additional issuances of equity or other potential financing will provide the necessary funding for the Company to continue as a going concern. The unaudited consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company is economically dependent upon future capital contributions or financing to fund ongoing operations.

Intangible_Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2013
Intangible Assets [Abstract]	'
INTANGIBLE ASSETS	'
	4.	INTANGIBLE ASSETS
	Licenses
	In terms of an Exclusive Patent License agreement covering national and international patents entered into with the Los Alamos National Security LLC dated September 8, 2005, the Company has the exclusive right to the use of certain patents covering the following:
	●	Method for Detecting Binding Events Using Micro X-Ray Fluorescence Spectrometry;
	●	Flow Method and Apparatus for Screening Chemicals Using Micro X-Ray Fluorescence;
	●	Method and Apparatus for Detecting Chemical Binding;
	●	Drug Development and Manufacturing.
	The agreement provides for a term as long as the last surviving patent which is generally a twenty-year period from the date of first application.
	In terms of the agreement, the Company issued shares to the Licensor equal to 3% of the issued equity of the Company. The agreement contains anti-dilutive clauses that will ensure that the Licensor maintains at least a 3% shareholding in the Company until the Company achieves equity financing of at least $20 million. The anti-dilutive clauses do not result in a freestanding instrument as they are directly linked to the shareholding that the Licensor currently holds in the Company. Should any percentage of that shareholding be sold to third parties, prior to the triggering of any anti-dilution event, the anti-dilution clause will be void for that percentage of the shareholding sold to third parties.   As of September 30, 2013, the Company has not yet raised the requisite amount of financing.  The Licensor continued to hold, at a minimum 3% of the Company’s common stock.
	The agreement has termination provisions as follows; i) at the option of the Licensor; if the Company fails to deliver any reports that are due, fails to pay any royalties or fees due, breaches any material clause of the agreement, or failure to inform the Licensor of a petition to file for voluntary or involuntary bankruptcy; ii) at the option of the Licensee by giving 90 days written notice to the Licensor.
	The agreement further provides for an annual royalty to be paid to the Licensee at a rate of 2% per annum on net sales, excluding any sales to Government agencies. The agreement provides for a minimum fee of $50,000 per annum up until December 31, 2022. The fee will be deducted from any royalties due in excess of the fee due for that financial year. The Company has not paid any royalties on a percentage basis, and has only paid the minimum fee since entering into the agreement.
	Future annual minimum payments required under license agreement obligations at September 30, 2013, are as follows:
			Amount
	2014		$	50,000
	2015			50,000
	2016			50,000
	2017			50,000
	2018 and thereafter			250,000
	Total		$	450,000
	Licenses consist of the following:
			September 30,			December 31,
			2013			2012
			(Unaudited)
	Licenses, at cost		$	972,000		$	972,000
	Less: Accumulated amortization			(416,189	)		(377,426	)
			$	555,811		$	594,574
	The aggregate amortization expense charged to operations was $12,921 for the three months ended September 30, 2013 and 2012, respectively and $38,763 for the nine months ended September 30, 2013 and 2012, respectively. The amortization policies followed by the Company are described in Note 2.
	Amortization expense for future periods is summarized as follows:
			Amount
	Remainder of 2013		$	12,921
	2014			51,684
	2015			51,684
	2016			51,684
	2017 and thereafter			387,838
	Total		$	555,811
	Patents
	The Company has various patents pending or registered in its name. These patents have been internally generated and all costs associated with the research and development of these patents has been expensed.
	The patents assigned to Caldera are as follows:
	●	Well Plate – apparatus for preparing samples for measurement by x-ray fluorescence spectrometry. Patent filed August 15, 2008
	●	Method and Apparatus for measuring Protein Post Translational Modification. Patent filed September 26, 2008.
	●	Method and Apparatus for Measuring Analyte Transport across barriers. Patent filed July 1, 2009.

Plant_and_Equipment

Plant and Equipment	9 Months Ended
	Sep. 30, 2013
Plant and Equipment [Abstract]	'
PLANT AND EQUIPMENT	'
	5.	PLANT AND EQUIPMENT
	Plant and equipment consists of the following:
			September 30,			December 31,
			2013			2012
			(Unaudited)
	Leasehold improvements		$	6,393		$	6,393
	Furniture and fittings			15,635			9,979
	Laboratory equipment			770,851			679,310
	Computer equipment			19,044			29,327
	Vehicles			17,658			17,658
	Total			829,581			742,667
	Accumulated depreciation			(418,502	)		(351,137	)
			$	411,079		$	391,530
	The aggregate depreciation charge to operations was $30,704 and $27,009 for the three months ended September 30, 2013 and 2012, respectively and $86,353 and $66,033 for the nine months ended September 30, 2013 and 2012 respectively. The depreciation policies followed by the Company are described in Note 2.

Other_Payables_and_Accrued_Exp

Other Payables and Accrued Expenses	9 Months Ended
	Sep. 30, 2013
Other Payables and Accrued Expenses [Abstract]	'
OTHER PAYABLES AND ACCRUED EXPENSES	'
	6.	OTHER PAYABLES AND ACCRUED EXPENSES
	Vacation and Sick Pay accrual
	117,018
	89,730
			September 30,		December 31,
			2013		2012
			(Unaudited)
	Short-term portion
	Credit card liabilities		$	20,038	$	7,505
	Other payables			82,800		97,972
	Payroll liabilities			60,184		-
	Other			2,100		2,100
				282,140		197,307
	Long-term portion
	Other payables			82,800		160,000
			$	364,940	$	357,307
	The repayment schedule of other payables is as follows:
			Amount
	Within 1 year		$	82,800
	1 to 2 years			82,800
	Total		$	165,600
	The other payables relates to the Bellows matter disclosed under Litigation in note 18 below.

Loans_Payable

Loans Payable	9 Months Ended
	Sep. 30, 2013
Loans Payable, Bridge Notes Payable and Notes Payable [Abstract]	'
LOANS PAYABLE	'
	7.	LOANS PAYABLE
			September 30,		December 31,
			2013		2012
			(Unaudited)
	Short term portion
	Los Alamos County project participation loan		$	32,459	$	31,270
	Los Alamos National Bank term loan			83,212		-
	Los Alamos National Bank revolving draw loan			-		168,827
	Los Alamos National Bank commercial loan			-		18,227
				115,671		218,324
	Long term portion
	Los Alamos County project participation loan			185,408		209,923
	Los Alamos National Bank term loan			184,898		-
	Los Alamos National Bank commercial loan			-		122,132
				370,306		332,055
	Total		$	485,977	$	550,379
	The amortization of the principal outstanding on the loans payable is as follows:
			Amount
	Within 1 year		$	115,671
	1 to 2 years			122,097
	2 to 3 years			128,954
	3 to 4 years			37,233
	Thereafter			82,022
	Total		$	485,977
	Los Alamos County project participation loan
	The Company entered into a Project Participation Agreement (as Amended) and a Loan Agreement with the Incorporated County of Los Alamos as of September 21, 2006. The Agreement provided for funding up to a maximum of $2,200,000 for the construction of a building and purchase of equipment. The maximum amount of equipment to be funded out of the total available loan of $2,200,000 was $625,000. The term of the loan is 13 years. The loan agreement provided for no repayments for 36 months with 120 equal monthly repayments commencing on September 21, 2009. The interest rate on the loan is 5% per annum. The assets funded in terms of the Project Participation Agreement and the Loan Agreement is to be used as security for the balance of the loan outstanding. The Company made use of the loan to purchase assets amounting to $302,009 during the 2007 financial year. Repayments of the loan commenced on September 21, 2009 at an interest rate of 5% per annum with equal monthly repayments of $3,547, inclusive of interest. The Company owed $217,867 and $241,193 as of September 30, 2013 and December 31, 2012, respectively.
	Los Alamos National Bank (“LANB”)
	The Company entered into a one year revolving draw loan with LANB for up to a maximum of $750,000 as of May 23, 2012. The loan bears interest at a coupon of the Wall Street Journal Prime rate plus 1.5% with a floor of 4.75% per annum. This loan is secured by accounts receivable and other rights to payments, instruments, documents and other chattel paper, general intangibles and fixed assets. Interest is payable quarterly. The Company drew $50,000 under this facility on May 23, 2012 to repay a previous and similar facility. An additional $118,000 was drawn down on this facility on July 11, 2012 to settle a liability owing to a supplier. On May 23, 2013, the revolving draw loan agreement was extended to August 23, 2013 and the availability under the facility was reduced to $167,943, the capital balance outstanding as of May 23, 2013. On September 16, 2013 the Company concluded a new term loan agreement, see below, with LANB and settled the outstanding balance, on this loan, inclusive of unpaid interest of $168,472.  The Company owed $168,827 as of December 31, 2012.
	The Company entered into a single advance commercial loan agreement with LANB for $148,500 on June 8, 2012. The purpose of this loan was to acquire an XRpro instrument. This loan bears interest at the Wall Street Journal Prime rate plus 1.5% with a floor of 6.00% per annum. This loan expires on June 8, 2019. The loan is repayable in 84 monthly installments of $2,169, inclusive of interest, which installment may vary depending on the variable interest rate mentioned above. This loan is secured by accounts receivable and other rights to payments, instruments, documents and other chattel paper, general intangibles and fixed assets. This loan has been advanced to both the Company and XRpro Corp., a wholly owned subsidiary, jointly and severally, and has been guaranteed by Dr. Benjamin Warner and his wife. On September 16, 2013 the Company concluded a new term loan agreement, see below, with LANB and settled the outstanding balance, on this loan, inclusive of unpaid interest of $126,501. The Company owed $140,359 as of December 31, 2012.
	On September 16, 2013 the Company concluded a term loan agreement with LANB to replace the revolving draw loan and the commercial loan disclosed above. The Company paid a combined $26,886 against the revolving draw line and the commercial loan and LANB advanced a new term loan to the Company of $267,392, the proceeds of which were used to settle the remaining balance, inclusive of interest, of the revolving draw line and the commercial loan. This loan bears interest at the Wall Street Journal Prime rate plus 2.0% with a floor of 7.0% per annum. This loan expires on September 16, 2016. The loan is repayable in 36 monthly installments of $8,256, inclusive of interest, which installment may vary depending on the variable interest rate mentioned above. This loan is secured by accounts receivable and other rights to payments, instruments, documents and other chattel paper, general intangibles and fixed assets. This loan has been advanced to both the Company and XRpro Corp., a wholly owned subsidiary, jointly and severally, and has been guaranteed by Dr. Benjamin Warner and his wife.

Bridge_Notes_Payable

Bridge Notes Payable	9 Months Ended
	Sep. 30, 2013
Loans Payable, Bridge Notes Payable and Notes Payable [Abstract]	'
BRIDGE NOTES PAYABLE	'
	8.	BRIDGE NOTES PAYABLE
	The Company entered into a 10% Bridge Note (the “Bridge Notes”) agreement with nine principals for $500,000 between December 18, 2012 and April 2, 2013. The Bridge Notes are issued as part of a unit that includes warrants to purchase 600 shares of the Company’s common stock for each $1,000 of Bridge Note principal, at an exercise price of $3.00 per share, see note 13 below. The Bridge Notes bear interest at 10% per annum compounded and payable quarterly at the Company’s option, until the maturity date which is defined as the earliest of December 31, 2013, or the closing of any subsequent financing transactions, or an event of default as defined in the agreement. The Bridge note agreement also provides for a default interest rate of 15% per annum should any amounts due to the note holders in terms of the agreement be in default.
	The Bridge Notes together with any interest due on the Bridge Notes will, at the option of the note holder, convert into securities of the Company’s subsequent financing. The Bridge Note holder also has the option to convert some or all of the principal and interest due on this note into shares of the Company’s common stock at a conversion price of $2.50 per share, unless a default has occurred and is continuing, at which instance the conversion price during the default period shall be $1.50 per share. The option to convert the Bridge Note into common stock has anti-dilutive provisions that will allow the note holder to be placed in the same position as it is prior to a dilution event occurring.
	On April 19, 2013, six principals converted their Bridge Notes in the aggregate principal amount of $375,000 together with accrued and unpaid interest thereon of $9,160 into 153,664 units of series B preferred units of the Company at a conversion price of $2.50 per unit, each unit consist of one share of series B preferred stock and one seven-year warrant exercisable at a price of $2.50 per share, which price is subject to anti-dilution protection, see note 11 and 13 below.
	On May 31, 2013 and August 30, 2013, the Bridge notes due to three principals of $100,000 and $25,000, together with accrued and unpaid interest thereon of $1,541 and $1,073, respectively, were repaid and cancelled.
	The Bridge Notes included a total discount of $118,232 relating to the fair value of the warrants issued together with those notes. The conversion of the $375,000 and the repayment of $125,000 of the Bridge Notes mentioned above resulted in the immediate amortization of $90,487 of this discount. The Bridge note discount amortized over the three months ended September 30, 2013 was $1,096.
			September 30,		December 31,
			2013		2012
			(Unaudited)
	Bridge notes payable		$	-	$	250,890
	Unamortized bridge note discount			-		-16,935
			$	-	$	233,955

Notes_Payable

Notes Payable	9 Months Ended
	Sep. 30, 2013
Loans Payable, Bridge Notes Payable and Notes Payable [Abstract]	'
NOTES PAYABLE	'
	9	NOTES PAYABLE
	The Company entered into a 10% Note (the “Notes”) agreement with two principals for $100,000 on March 25, 2013. The Notes bear interest at 10% per annum compounded and payable quarterly at the Company’s option, until the notes are repaid. These notes were utilized to provide temporary funding and were repaid, together with accrued interest on April 4, 2013.

Derivative_Financial_Liability

Derivative Financial Liability	9 Months Ended
	Sep. 30, 2013
Derivative Financial Liability [Abstract]	'
DERIVATIVE FINANCIAL LIABILITY	'
	10	DERIVATIVE FINANCIAL LIABILITY
	The warrants arising from the issue of the Bridge notes (“Bridge Warrants”) disclosed under note 8 above have anti-dilution protection, whereby the exercise price of the warrant will re-price, based on a pre-determined formula, if any securities are sold, exercisable or convertible at a price less than the exercise price of the Bridge Warrants. This gives rise to a derivative financial liability, which was valued at $118,232 as of September 30, 2013 using a Black-Scholes valuation model. The value of this derivative financial liability will be re-assessed at each financial reporting period, with any movement thereon recorded in the statement of income in the period in which it is incurred.
	The warrants arising from the issue of the series B preferred units (“Series B Shares”), together with the placement agent warrants directly related to that issue, disclosed under note 13 below have anti-dilution protection, whereby the exercise price of the warrant will re-price, based on a pre-determined formula, if any securities are sold, exercisable or convertible at a price less than the exercise price of the series B warrants. This gives rise to a derivative financial liability, which was valued at $1,745,836 and recorded as a deemed dividend expense, as of the date of issuance of the series B shares using a Black-Scholes valuation model. The value of this derivative financial liability will be re-assessed at each financial reporting period, with any movement thereon recorded in the statement of income in the period in which it is incurred.
	The value of the derivative financial liability was re-assessed as of September 30, 2013 resulting in a net credit to the unaudited consolidated statement of operations of $388,093 for the nine months ended September 30, 2013.
			September 30,			December 31,
			2013			2012
			(Unaudited)
	Opening balance		$	17,539		$	-
	Derivative financial liability arising on bridge warrants with re-pricing terms			100,693			17,539
	Derivative financial liability arising on the issue of warrants relating to Series B shares			1,745,836			-
	Fair value adjustments			(388,093	)		-
			$	1,475,975		$	17,539
	The following assumptions were used in the Black-Scholes valuation model:
			Nine months ended
			September 30,
			2013
	Calculated stock price		$1.13- $1.27
	Risk-free interest rate		0.02% to 0.07%
	Expected life of warrants		5 Years
	Expected volatility of the underlying stock		100% -164%
	Expected dividend rate		0%

Preferred_Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2013
Common Stock and Preferred Stock [Abstract]	'
PREFERRED STOCK	'
	11	PREFERRED STOCK
	Preferred Stock consists of 10,000,000 authorized preferred shares of $0.001 par value each. The articles of Incorporation were amended on April 10, 2012 to change the designation of all of the 10,000,000 preferred shares of $0.001 each, from Series A 8% convertible redeemable preferred shares to 400,000 Series A 8% convertible redeemable preferred shares of $0.001 each. On April 19, 2013, the articles of incorporation were again amended to change the designation of the remaining 9,600,000 preferred shares to 3,000,000 Series B convertible  preferred shares of $0.001 each, with the remaining 6,600,000 preferred shares remaining undesignated.
	Series A 8% Convertible, Redeemable Preferred Stock (“Series A Stock”)
	Series A Stock consists of 400,000 designated shares of $0.001 par value each, 105,000 and 341,607 shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively.
	On April 30, 2013, the holders of 341,607 Series A Stock entered into an agreement to exchange their Series A Stock into 778,860 series B preferred shares of the Company. The number of series B preferred shares issued was derived at by dividing the total dollar investment made in the Company by each Series A stockholder by $2.50. In addition to this a further 83,423 series B preferred shares of $2.50 each were issued to the Series A stockholders in lieu of dividends due as of April 30, 2013.
	On May 20, 2013, in terms of a legal settlement agreement entered into with Joel Bellows (Refer note 18 below), 105,000 Series A Stock was issued in exchange for his 105,000 common shares held in the Company. The Series A Stock issued to Joel Bellows was valued at $133,350 using a Black Scholes valuation model, the assumptions which are disclosed under note 10 above.
	Conversion
	The Series A Stock will convert to common stock of the Company at a price of $5.70 per share of Common Stock subject to adjustment for stock splits, stock dividends and any further recapitalizations. The Series A Stock is subject to voluntary conversion at the option of the stockholder at any time and is mandatory convertible at the option of the Company provided the Company’s common stock is trading on a recognized stock exchange or Over the Counter Bulletin Board and the volume weighted average price of the Company’s common stock is at least $10 per share, subject to stock splits, stock dividends and recapitalizations.
	Warrants
	The original holders of Series A Stock had received warrants to purchase 341,607 shares of the Company’s common stock at an exercise price of $5.70 per share. The warrants expire five years after date of issuance. In terms of the exchange agreement entered into with the Company on April 30, 2013, these warrants remain in place. These warrants are not transferable without the consent of the Company and an opinion of Counsel satisfactory to the Company.
	Redemption
	Should the Company receive net proceeds of at least $3 million from litigation proceedings against the Regents of the University of California and Los Alamos National Security (see note 18); the remaining Series A stockholders will have the option to redeem the Series A Stock equal to 130% of the initial investment in the Company by the stockholder, which amounted to $210,000. This value differs from the carrying value of the Series A Stock of $133,350 which was valued using the Black-Scholes valuation model at the time of exchanging common stock for Series A Stock (Refer note 18 below). The Company also has the option to redeem the Series A Stock at a price equal to 130% of the initial investment in the Company by the stockholder at any time after giving the investors notice and allowing them to exercise their conversion rights into common stock 30 days after notice has been received. The Company is not obligated to pursue the litigation against Los Alamos National Laboratory but is doing so based on its belief that it will have a successful outcome.
	Liquidation
	The liquidation rights of the Series A Stock is the greater of $5.70 per share plus any unpaid dividends or an amount that would have been payable had all shares of Series A Stock converted into common stock immediately prior to liquidation.
	Dividends
	The Series A Stock carries an 8% cumulative, non-compounded dividend payable on January 31st, each year in cash or in kind at the option of the Series A stockholder. For any other dividends or distributions, the Series A Stock is treated on an as- converted basis.
	An accrual for Series A Stock dividends of $69,268 and $117,373 was made for the nine month ended as of September 30, 2013 and 2012, respectively.
	Series B Convertible Preferred Stock (“Series B Stock”)
	Series B Stock consists of 3,000,000 designated shares of $0.001 par value each and 2,133,947 and nil shares issued and outstanding as of September 30, 2013 and December 31, 2012, respectively.
	In connection with the terms of the recent private placement:
	●	Six principals converted their Bridge Notes of $375,000 together with accrued and unpaid interest thereon of $9,160 into 153,664 Series B preferred units of the Company at a conversion price of $2.50 per unit, each unit consists of one share of Series B Stock and one seven-year common stock purchase warrant exercisable at a price of $2.50 per share, see note 13 below.
	●	New, qualified investors, acquired 1,118,000 Series B preferred units of the Company at a price of $2.50 per unit, each unit consisting of one share of Series B Stock and one seven-year common stock purchase warrant at an exercise price of $2.50 per share, for net proceeds of $2,509,700 after deducting placement agent fees of $285,300 based on the Series B preferred units issued to new investors and the conversion of the Bridge Notes mentioned above.
	In terms of exchange agreements entered into with the holders of 341,607 Series A shares, 778,860 shares of Series B Stock of $2.50 each were issued to the Series A stockholders by dividing their initial dollar investment in the Series A Stock by $2.50. In addition to this a further 83,423 shares of Series B Stock of $2.50 each was issued to the Series A shareholders in lieu of dividends accrued and due to the Series A shareholders as of April 30, 2013.
	●
	The following is a summary of material provisions of the Series B Stock as set forth in the Certificate of Designations.
	Dividends
	Series B Stock accrue dividends at the rate per annum equal to (i) 8% of the sum of (x) the Stated Value and (y) the amount of accrued and unpaid dividends payable, out of funds legally available for payment, on January 31st of each year, if paid in cash, or (ii) 10% of the sum of (x) the Stated Value and (y) the amount of accrued and unpaid dividends payable, out of funds legally available for payment, on January 31st of each year, if paid in shares of Common Stock, based upon a price of $2.50 per share of Common Stock. The Company shall have the option, to pay any such dividends in cash or shares of Common Stock. Such dividends shall be in preference and priority to any payment of any dividend on Common Stock, or any other class of preferred stock. Dividends are cumulative.
	An accrual for Series B Stock dividends of $224,786 was made for the nine months ended September 30, 2013.
	Conversion
	Subject to adjustment as more fully described herein, each Series B Stock is currently convertible at the option of the holder into one share of Common Stock. Each Series B Stock (together with any accrued but unpaid dividends thereon) is convertible into shares of Common Stock at the option of the holder at any time at a conversion price per share equal to the sum of the Stated Value and any accrued but unpaid dividends thereon through the date of notice of conversion divided by the Conversion Price, subject to adjustment as described below. The initial Conversion Price shall be equal to the Stated Value. If the Company merges or sells its assets, holders of Series B Stock will be entitled to receive on conversion the securities or property (including cash) of the successor corporation that they would have received as a result of that merger or sale if they had converted immediately beforehand. At any time after the Common Stock is listed on a national securities exchange as defined in the Securities Exchange Act of 1934, the Company may cause the conversion of the Series B Stock, plus accrued but unpaid dividends into shares of Common Stock, each Series B Stock convertible into such number of shares of Common Stock as shall equal the sum of the Stated Value plus any accrued but unpaid dividends through the date of conversion divided by the lower of the then conversion price and the market price of the Company’s Common Stock. Market Price is defined as the average of the reported closing sales price of the Common Stock for each of the five trading days for which a closing sales price is reported immediately preceding the day prior to the conversion.
	Liquidation
	In the event of a liquidation, dissolution or winding up of the Company and other Liquidation Events as defined in the Certificate of Designations, holders of Series B Stock are entitled to receive from proceeds remaining after distribution to the Company’s creditors and prior to the distribution holders of Common Stock or any other class of preferred stock the (x) Stated Value (as adjusted for any stock splits, stock dividends, reorganizations, recapitalizations and the like) held by such holder and (y) all accrued but unpaid dividends on such shares.
	Anti-Dilution
	If the Company issues Common Stock or securities convertible, exercisable or exchangeable into Common Stock for a purchase price of less than $2.50 per share then the holders of the Series B Stock will be entitled to a weighted-average” adjustment in the number of common shares that their Series B Stock can be converted into; provided, however, that there will be no adjustment to the number of shares of Common Stock that the Series B Stock can be converted into for (i) issuance or sale of Common Stock or options or other awards under the Corporation’s equity incentive plans or programs not to exceed 2,000,000 shares of Common Stock; (ii) issuance or sale of preferred stock or Common Stock issuable upon conversion, exchange or exercise of the Series A Stock or Series B Stock, the Bridge Notes, the Warrants issued in connection with the exchange of the Bridge Notes, the Warrants issued in connection with the issuance of the Series B Stock to the holders thereof, any Warrants issued to the Placement Agent or its designees in connection with the issuance of the Series B Stock or as an advisory fee or any other convertible securities or warrants outstanding on the date hereof; (iii) issuance of equity securities or rights to purchase equity securities issued in connection with commercial property or lease transactions that are approved by the Board of Directors; (iv) issuance of equity securities or rights to purchase equity securities issued for consideration other than cash pursuant to a merger, consolidation, acquisition or similar business combination approved by the Board of Directors; (v) issuance of securities to an entity as a component of any business relationship with such entity primarily for the purpose of (A) joint venture, technology or licensing development activities; (B) distribution, supply or manufacture of the Company’s products or services; or (C) any other arrangements involving corporate partners primarily for purposes other than raising capital, the terms of which business relationship with such entity are approved by the Board of Directors; and (vi) issuance of stock pursuant to a stock dividend or stock split.
	Series B Convertible Preferred Stock (“Series B Stock”) (continued)
	Voting
	Except as otherwise required by law and except as set forth below, holders of Series B Stock will, on an as-converted basis, vote together with the Common Stock as a single class. Each holder of Series B Stock is entitled to cast the number of votes equal to two times the number of shares of Common Stock into which such shares of Series B Stock could be converted at the record date for determining stockholders entitled to vote at the meeting. The approval by holders of a majority of the Series B Stock, voting separately as a class, will be required for the creation of any class or series of preferred stock ranking senior to or pari passu with the Series B Stock as to payments of dividends or upon the liquidation of the Company.
	Financials
	As soon as practicable after the filing of the Company’s Quarterly Report on Form 10-Q and its Annual Report on Form 10-K, the Holders of the Series B Stock shall be entitled to receive, upon request, a consolidated balance sheet of the Company, if any, as of the end of such fiscal year or quarter, and consolidated statements of operations and consolidated statements of cash flows and stockholders’ equity of the Company, if any, for such year or quarter, prepared in accordance with generally accepted accounting principles and setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail.

Common_Stock

Common Stock	9 Months Ended
	Sep. 30, 2013
Common Stock and Preferred Stock [Abstract]	'
COMMON STOCK	'
	12	COMMON STOCK
	Common stock consists of 50,000,000 authorized shares of $0.001 each, 4,851,270 and 4,956,270 shares issued and 4,197,270 and 4,302,270 shares outstanding as of September 30, 2013 and December 31, 2012, respectively.
	On May 20, 2013, in terms of a legal settlement agreement entered into with Joel Bellows (See note 18 below), 105,000 common shares were exchanged for 105,000 Series A Stock. The common shares exchanged were cancelled and are available for reissue.
	During the year ended December 31, 2012 a further 10,650 shares of common stock were issued at $5.70 per share for a total of $60,705 in lieu of Series A Stock dividends which were due at January 31, 2012.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2013
Warrants [Abstract]	'
WARRANTS	'
	13	WARRANTS
	In connection with the terms of the recent private placement:
	●	Warrants to purchase 153,664 shares of common stock at a purchase price of $2.50 per shares were issued to Bridge Note holders upon conversion of their Bridge Notes into series B units as disclosed in note 11 above. These warrants have a seven-year term and are exercisable at the option of the holder. These warrants may be exercised for shares of common stock in lieu of cash by applying the number of warrants to the formula whereby the exercise price of the warrants is deducted from the closing price of the common stock on a quoted market divided by the closing price of the common stock on a quoted market. These warrants also have dilution protection in certain instances.
	●	Warrants to purchase 1,118,000 shares of common stock at a purchase price of $2.50 per shares were issued to new qualified investors in series B units as disclosed in note 11 above. These warrants have a seven-year term and are exercisable at the option of the holder. These warrants may be exercised for shares of common stock in lieu of cash by applying the number of warrants to the formula whereby the exercise price of the warrants is deducted from the closing price of the common stock on a quoted market divided by the closing price of the common stock on a quoted market. These warrants also have dilution protection in certain instances.
	●	Warrants to purchase 286,800 shares of common stock at a purchase price of $2.75 per share and a further 40,000 warrants to purchase shares of common stock at $0.01 per share were issued to the placement agent as placement agent fees and advisory fees. These warrants have a seven-year term and are exercisable at the option of the holder. These warrants may be exercised for shares of common stock in lieu of cash by applying the number of warrants to the formula whereby the exercise price of the warrants is deducted from the closing price of the common stock on a quoted market divided by the closing price of the common stock on a quoted market. These warrants also have dilution protection in certain instances.
	In terms of Bridge Note agreements entered into with certain principals during the nine months ended September 30, 2013 and the year ended December 31, 2012 warrants for the purchase of 300,000 shares of common stock at an exercise price of $3.00 per share were issued to Bridge Note holders in conjunction with the Bridge notes disclosed in note 8 above. These warrants have a five-year term and are exercisable at the option of the holder. These warrants may be exercised for shares of common stock in lieu of cash by applying the number of warrants to the formula whereby the exercise price of the warrants is deducted from the closing price of the common stock on a quoted market divided by the closing price of the common stock on a quoted market. These warrants also have dilution protection in certain instances.
	During the year ended December 31, 2012 warrants for the purchase of 10,088 shares of common stock at an exercise price of $5.70 per share were issued to investors in conjunction with the issuance of 10,088 shares of Series A Stock. These warrants have a five-year term and are exercisable at the option of the holder.
	The fair value of these warrants was determined using the Black-Scholes valuation model. The following assumptions were used:
			Nine months ended			Year ended
			September 30,			December 31,
			2013			2012
	Calculated stock price			$1.13- $1.27			$0.55
	Risk-free interest rate		0.02% to 0.07%			0.01% to 0.15%
	Expected life of warrants		5 - 7 Years			5 Years
	Expected volatility of the underlying stock			100% - 164%			157%
	Expected dividend rate			0%			0%
	A fair market value of $1,745,836, determined using the Black-Scholes valuation model with the assumptions listed above, for the 1,271,664 warrants issued in conjunction with the Series B Stock offering and the 326,800 warrants issued as placement agent and advisory fees for that offering, was recorded as a deemed preferred stock dividend during the nine months ended September 30, 2013.
	The additional 300,000 warrants issued during the nine months ended September 30, 2013 and December 2012 in conjunction with the Bridge notes were valued using the Black-Scholes model with the assumptions listed above and a discount of $100,693 and $17,539, respectively was applied to the Bridge Notes and has been fully amortized, see note 8 above.
	A fair market value for the 10,088 warrants issued in conjunction with the Series A Stock of $2,857 was recorded as a deemed preferred stock dividend during the 2012 year.
	The following table summarizes warrants outstanding and exercisable as of September 30, 2013:
				Warrants Outstanding						Warrants Exercisable
	Exercise Price			Number of	Weighted			Weighted Average		Number of		Weighted Average
				shares	average			Exercise Price		Shares		exercise Price
					remaining
					contractual
					years
	$	0.01		40,000		6.75					40,000
	$	2		15,000		3.07					15,000
	$	2.5		1,271,664		6.58					1,271,664
	$	2.75		286,800		6.75					286,800
	$	3		300,000		4.36					300,000
	$	5.7		384,407		2.69					384,407
				2,297,871		5.64		$	3.09		2,297,871	$	3.09

Stock_Based_Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2013
Stock Based Compensation [Abstract]	'
STOCK BASED COMPENSATION	'
	14.              STOCK BASED COMPENSATION
	In October 2005, the Company's Board of Directors adopted the Caldera Pharmaceuticals, Inc. 2005 Stock Option Plan (the "Plan"), which permits awards of incentive and nonqualified stock options and other forms of incentive compensation to employees and non-employees such as directors and consultants. The Board has set aside 3,000,000 shares of common stock for issuance upon exercise of grants made under the Plan. Options granted under the Plan vest either immediately or over a period of up to two years, and expire 1 year to 10 years from the grant date. At September 30, 2013, 1,365,946 shares were available for future grant under the Incentive Plan.
	Stock option based compensation expense totaled $441,566 and $48,852 for the nine months ended September 30, 2013 and 2012, respectively. The Company expenses the value of stock options on a straight line basis over the life of the options. The fair value of the options granted is determined using the Black-Scholes option-pricing model.
	The following weighted average assumptions were used:
			Nine			Year ended
			months ended			December 31,
			September 30,			2012
			2013
	Calculated stock price		$1.13 to $1.27			$0.55
	Risk-free interest rate		0.02% to 0.07%			0.01% to 0.15%
	Expected life of options		5 Years			5 Years
	Expected volatility of the underlying stock		100 - 164%			128%
	Expected dividend rate		0%			0%
	As noted above, the fair value of stock options is determined by using the Black-Scholes option-pricing model. For all options granted since October 1, 2005 the Company has generally used option terms of between 1 to 10 years. The volatility of the common stock is estimated using historical data of companies similar in size and in the same industry as Caldera Pharmaceuticals.  The risk-free interest rate used in the Black-Scholes option-pricing model is determined by reference to historical U.S. Treasury constant maturity rates with short-term maturities of no more than three months. An expected dividend yield of zero is used in the option valuation model, because the Company does not expect to pay any cash dividends in the foreseeable future. As of September 30, 2013, the Company does not anticipate any awards will be forfeited in the calculation of compensation expense due to the limited number of employees that receive stock option grants.
	No options were exercised for the nine months ended September 30, 2013 and the year ended December 31, 2012.
	We canceled options exercisable for 37,000 and 59,291 shares of common stock for the nine months ended September 30, 2013 and the year ended December 31, 2012, respectively, held by employees whose service to our company terminated during those respective periods. The shares underlying such options were returned to and are available for re-issuance under the 2005 Plan pursuant to the terms described above.
	During the nine months ended September 30, 2013 and the year ended December 31, 2012, all awards granted under the Plan were incentive stock options. A summary of all of our option activity during the period January 1, 2012 to September 30, 2013 is as follows:
							Exercise		Weighted
			Shares				price per		average
							share		exercise price
	Outstanding January 1, 2012			518,445			$	2.00 - 5.71	$	3.54
	Granted			47,000				0.20 - 5.71		1.97
	Forfeited/Cancelled			(59,291	)			1.10 - 5.71		5.71
	Exercised			-				-		-
	Outstanding December 31, 2012			506,154			$	0.20 - 5.71	$	3.14
	Granted			1,164,900				1.50 – 5.71		1.99
	Forfeited/Cancelled			(37,000	)			2.00 -5.71		3.93
	Exercised			-				-		-
	Outstanding September 30, 2013			1,634,054			$	0.20 - 5.71	$	2.31
	Stock options outstanding as of September 30, 2013 and December 31, 2012, as disclosed in the above table, have an intrinsic value of $33,325 and $0, respectively.
	The following tables summarize information about stock options outstanding as of September 30, 2013:
					Options Outstanding						Options Exercisable
	Exercise Price				Number of		Weighted		Weighted		Number of		Weighted
					shares		average		Average		Shares		Average
							remaining		Exercise Price				exercise Price
							contractual
							years
	$	0.2			30,000			8.59				27,500
	$	1.1			220,000			7.42				220,000
	$	1.5			625,000			9.46				312,504
	$	2			15,000			2.12				15,000
	$	2.5			524,900			6.81				-
	$	5.71			219,154			5.1				219,154
					1,634,054			7.67	$	2.31		794,158	$	2.52
	The weighted-average grant-date fair values of options granted during the nine months ended September 30, 2013 and the year ended December 31, 2012 was $1,282,147 ($1.10 per option) and $17,068 ($0.46 per option), respectively. As of September 30, 2013 there were unvested options to purchase 839,896 shares of common stock. Total expected unrecognized compensation cost related to such unvested options is $833,356, which is expected to be recognized over a period of 45 months.
	Subsequent to the nine months ended September 30, 2013, options over 20,000 shares were issued to a newly appointed board member, see note 19 below.

Net_Loss_Per_Common_Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2013
Net Loss Per Common Share [Abstract]	'
NET LOSS PER COMMON SHARE	'
	15.              NET LOSS PER COMMON SHARE
	Basic loss per share is based on the weighted-average number of common shares outstanding during each period. Diluted loss per share is based on basic shares as determined above plus the incremental shares that would be issued upon the assumed exercise of in-the-money stock options and warrants using the treasury stock method. The computation of diluted net loss per share does not assume the issuance of common shares that have an anti-dilutive effect on net loss per share. For the three months and nine months ended September 30, 2013 and 2012 all stock options, warrants and convertible preferred stock were excluded from the computation of diluted net loss per share. Dilutive shares which could exist pursuant to the exercise of outstanding stock instruments and which were not included in the calculation because their affect would have been anti-dilutive are as follows:
		Nine months ended		Nine months ended
		September 30,		September 30,
		2013		2012
		(Shares)		(Shares)
	Options to purchase shares of common stock		1,634,054		477,967
	Series A convertible, redeemable preferred stock		105,000		341,607
	Series B convertible preferred stock		2,133,947		-
	Warrants		2,297,871		399,407
			6,170,872		1,218,981

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	16.              RELATED PARTY TRANSACTIONS
	The majority of the common shares in the Company are owned by Dr. Benjamin Warner, the Chief Scientific Officer. As of September 30, 2013 and December 31, 2012, Dr. Benjamin Warner owned 76.0% and 74.1%, respectively of the issued and outstanding shares of common stock on an un-diluted basis.
	Effective March 15, 2013 the Company entered into a five year employment agreement with Dr. Warner to continue to serve as the Company’s Chief Executive Officer (“CEO”) and President (the “Employment Agreement”). The Employment Agreement replaces his prior agreement.  Pursuant to the Employment Agreement, Dr. Warner will be entitled to an annual base salary of $250,000 and will be eligible for discretionary performance and transactional bonus payments as well as certain other specified benefits. Additionally, Dr. Warner was granted options to purchase 185,000 shares of the Company’s common stock with an exercise price equal to $1.50 per share. These options will vest pro rata, on a monthly basis over twelve months, with 15,417 vesting each month commencing April 1, 2013. The Employment Agreement also includes confidentiality obligations and inventions assignments by Dr. Warner.
	Effective April 30, 2013, Dr. Benjamin Warner entered into an Exchange Agreement whereby 25,035 shares of Series A Stock and accrued and unpaid dividends up until April 30, 2013 of $15,300 were converted into 63,201 shares of Series B Stock, see note 11 above.
	During July 2013, a new CEO and President of the Company was appointed, and Dr. Benjamin Warner relinquished his position as CEO and President and accepted the appointment as Chief Scientific Officer. The terms of his Employment Agreement remain unchanged.
	During July 2013, the Company entered into an employment agreement to appoint Mr. Gary Altman as the Chief Executive Officer and President of the Company. The employment agreement is for a term of four years, pursuant to which Mr. Altman will be entitled to an annual base salary of $300,000, increasing to $325,000 on the first anniversary of the employment agreement and will also entitle Mr. Altman to discretionary performance and transactional bonus payments as well as certain other specified benefits. Additionally, Mr. Altman was granted options to purchase 514,900 shares of the Company’s common stock at an exercise price of $2.50 per share. These options will vest as to 64,360 six months after the effective date of the contract and the remaining options will vest equally over the following forty-two month period. The Employment Agreement also includes confidentiality obligations and inventions assignments by Mr. Altman.

Operating_Leases

Operating Leases	9 Months Ended
	Sep. 30, 2013
Operating Leases [Abstract]	'
OPERATING LEASES	'
	17.              OPERATING LEASES
	The Company entered into a laboratory and office lease agreement for 2,813 square feet in Cambridge, Massachusetts effective June 1, 2013. The term of the lease is for a twelve month period terminating on May 31, 2014. The monthly rental amounts to $15,118. Rental expense for the nine months ended September 30, 2013 amounted to $61,795.
	The Company entered into a corporate apartment lease agreement in Cambridge, Massachusetts effective June 4, 2013. The term of the lease is for a twelve month period terminating on June 3, 2014. The monthly rental amounts to $3,325. Rental expense for the nine months ended September 30, 2013 amounted to $14,243.
	The Company extended its existing office lease in New Mexico effective November 1, 2010. The monthly rent amounts to $5,075 per month and the lease terminates in October 2013. Rental expense for the nine months ended September 30, 2013 and 2012 was $45,678 and $44,348, respectively.
	Future annual minimum payments required under operating lease obligations as of September 30, 2013, are as follows:
		Amount
	2013	$	60,404
	2014		92,214
		$	152,618

Litigation

Litigation	9 Months Ended
	Sep. 30, 2013
Litigation [Abstract]	'
LITIGATION	'
	18.              LITIGATION
	Suit against The Regents of the University of California, Los Alamos National Security, et al.
	The Company filed suit against the Regents of the University of California (the “Regents”) and Los Alamos National Security LLC (“LANS”) in California Superior Court in San Francisco in December 2007. This suit alleges (i) breach of contract and (ii) fraud in connection with an exclusive Patent Licensing Agreement (the “Agreement”) originally entered into between the Company and the Regents in September 2005, and assigned to LANS in April 2006. The Company alleges the defendants made false representations that were critical to its decision to enter into the Agreement including: (i) the Regents was the lawful owner of the patent rights covered by the Agreement; and (ii) the Regents would prosecute and maintain these patent rights and notify the Company if it decided to abandon them. The Company also alleges that the Regents and LANS improperly competed with the Company in violation of the exclusivity provision of the Agreement.  The Company is seeking relief for compensatory damages potentially in excess of $600 million, as well as exemplary and punitive damages, interest, and costs. This suit was dismissed for reason of lack of subject matter jurisdiction by the California Superior Court in 2010.  On April 24, 2012, the trial Court’s dismissal for lack of subject matter jurisdiction was reversed in full by the California Court of Appeal. The defendants unsuccessfully attempted to appeal this decisions to the California Supreme Court and, subsequently, to the Supreme Court of the United States. On February 25, 2013, the Supreme Court denied defendants’ petition for certiorari and the matter was remitted to California Superior Court.  On March 22, 2013, The Regents and LANS moved to re-file certain counterclaims against the Company and Benjamin Warner that had been dismissed voluntarily without prejudice after the matter was dismissed for lack of subject matter jurisdiction in 2010.   The motion was granted in May 2013 and, shortly thereafter, the Regents and LANS filed cross- and counter-claims against the Company and Dr. Warner.  The Company believes these counterclaims to be wholly without merit, and intends to vigorously defend against them.  No assurance can be given as to the ultimate outcome of these actions or their effect on the Company.  If the Company is not successful in its defense of these counterclaims it would have a material adverse effect on the pending litigation, the Company and its operations. On August 5, 2013, the Company filed a demurrer against certain of the causes of action against the Company. Dr. Warner filed a motion to quash service for a lack of personal jurisdiction. The court set a trial date for July 14, 2014. Merits discovery in the California matter has re-commenced.
	In October 2010, the Company filed suit against LANS and seven other co-defendants in the United States District Court For the Northern District of Illinois Eastern Division alleging the following: (i) breach of contract; (ii) fraud; (iii) intentional interference with contractual relations; and (iv) conspiracy and other related claims in connection with the September 2005 Agreement that was assigned to LANS in April 2006.  The Company alleges the defendants made false representations that were critical to its decision to enter into the Agreement including: (i) the Regents was the lawful owner of the patent rights covered by the Agreement and (ii) the Regents would prosecute and maintain these patent rights and notify the Company if it decided to abandon them.  The Company also alleges that LANS and other co-defendants improperly competed with the Company.  The Company is seeking relief including compensatory damages in excess of $600 million, as well as exemplary and punitive damages, interest, and costs.  In January 2012, this case was ordered to be transferred to Federal Court in New Mexico.  In February 2012, the case was transferred to Federal Court in New Mexico.  On May 4, 2012 LANS filed counterclaims in New Mexico Federal Court against the Company and Dr. Warner making various claims of ownership to the Company’s existing intellectual property and seeking unspecified damages.  The Company believes these counterclaims to be wholly without merit, and intends to vigorously defend against them.  No assurance can be given as to the ultimate outcome of these actions or their effect on the Company.  If the Company is not successful in its defense of these counterclaims it would have a material adverse effect on the pending litigation, the Company and its operations.  This matter is currently stayed. After the Regents and LANS exhausted their appeal in the California action, and the California action was remitted to California state court, on July 24, 2013, the Company moved to have the New Mexico district court action, including cross- and counter-claims, dismissed for lack of subject matter. The court has not yet ruled on the Company’s motion.
	In September 2011, the Company filed suit against the Regents and LANS in the Circuit Court of Cook County, Illinois (“Cook County Action”).   The Company's complaint alleges the following: (i) breach of contract; (ii) breach of the implied covenant of good faith; (iii) fraud; and (iv) fraudulent inducement, in connection with the September 2005 Agreement with the Regents assigned to LANS in April 2006.  The Company alleges the defendants breached a License Agreement, and made false representations that were critical to the Company's decision to enter into the Agreement.  The Company also alleges that the Regents and LANS improperly competed with the Company in violation of the exclusivity provision of the Agreement.  The Company is seeking relief for compensatory damages in excess of $600 million, as well as exemplary and punitive damage, interest, and costs. LANS removed the case to the United States District Court for the Northern District of Illinois Eastern Division, Case # 11-CV-07259.  In March 2012, the Company filed a motion to remand the case to the Circuit Court of Cook County, and on May 11, 2012 the case was remanded to the Circuit Court of Cook County.  The Company then amended the complaint in October 2012 to include claims against UChicago Argonne and Liaohai Chen, a manager and scientist at Argonne, for intentional interference with contractual relations and related claims.  The Company also added conspiracy claims against all defendants.  Argonne removed the case to United States District Court for the Northern District of Illinois Eastern Division on October 22, 2012.  The Company moved to remand the action back to the Circuit Court of Cook County and on February 1, 2013, the matter was remanded.  On April 24, 2013, the Company filed a Second Amended Complaint alleging essentially the same causes of action.  After the Regents and LANS exhausted their appeal in the California action, and the Californai action was remitted to California state court, the Company moved to have the Cook County matter dismissed. On July 26, 2013, the court entered an order dismissing the action, in its entirety, without prejudice.
	The Company has a contingency fee arrangement for legal expenses in connection with the litigation against the Regents of the University of California and Los Alamos National Security, LLC, et al. The fees involved are contingent upon the successful outcome of this litigation and will not be due if we are unsuccessful. A small percentage of the fees are currently subject to a negotiation with the law firm in question. The maximum estimated contingency fee arrangement is dependent on the successful outcome of the matters and the negotiation with the law firm, as of September 30, 2013, amounts to $2,177,463.
	Joel Bellows Suit
	In October 2008, Seddie Bastanipour and Joel Bellows filed suit against the Company, Dr. Benjamin Warner, and a former consultant to the Company, Sigmund Eisenchenk. Joel Bellows provided legal services to the Company through his legal firm, Bellows and Bellows P.C. The suit was filed in the Circuit Court of Cook County, Illinois and alleged the following: (i) Violation of Illinois Securities Act of 1953; (ii) Violation of Illinois Consumer Fraud Act; and (iii) Common Law Fraud, in connection with aggregate investments of $218,000 in the Company’s common stock claimed by Bastanipour and Bellows. They are seeking compensatory damages, costs and expenses.
	In March, 2010, the Company filed suit against Joel Bellows and Bellows and Bellows P.C. in the United States District Court for the District of New Mexico alleging the following: (i) Breach of Contract; (ii) Negligence; (iii) Breach of Fiduciary Duty; (iv) Fraud; and (v) Tortious Interference with Contract. The aforementioned complaints relate to legal services provided by Bellows and Bellows P.C. for the Company. The Company is seeking compensatory damages, punitive damages, interest, costs and fees.
	In December 2010, the Company filed suit against Seddie Bastanipour and Peter Baltrus for breach of contract and negligence when they were performing accounting services on behalf of the Company that resulted in an IRS penalty.
	In December 2011, the Company completed an amicable settlement with Bastanipour with respect to the October 2008 and December 2010 suits that is subject to confidentiality restraints and she is no longer party to either suit. The settlement did not have a material impact on our financial position.
	In February 2013 a settlement agreement was entered into between the Company, Joel Bellows and Peter Baltrus, with respect to the October 2008 and December 2010 suits, which requires the exchange of 105,000 common shares for 105,000 shares of Series A Stock or Series B Stock and a cash payment of $240,000, together with interest thereon at 6% per annum, over a three-year period.  An accrual of $257,972 had been recorded to deal with this matter as of December 31, 2012. A further legal settlement expense of $115,273 was recorded to reflect the fair market value of the Series A Stock issued to Mr. Bellows during the nine months ended September 30, 2013.
	On April 30, 2013, the October 2008 and the December 2010 suits were dismissed, with prejudice.  In terms of this settlement agreement, the Company paid the first cash installment of $80,000 during March 2013 and on May 20, 2013, issued 105,000 shares of Series A Stock to Joel Bellows, in exchange for his 105,000 common shares. The Company and Dr. Benjamin Warner have filed post-settlement motions for the Judge in the matter to reconsider his May 16, 2013 ruling wherein the Company and Dr Benjamin Warner were compelled to comply with a disputed version of the settlement agreement which entitled Bellows to a prejudicial conversion formula of his Series A Stock into Series B Stock which is contrary to our settlement intentions. The motion was heard on September 25, 2013 and denied. On October 24, 2013, the Company and Dr. Benjamin Warner filed a notice of appeal.
	Subsequent to the period end, on October 4, 2013, the March 2010 suit was dismissed with prejudice and a settlement agreement was entered into. In terms of this settlement agreement the Company received a net $30,000 cash settlement.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	19.              SUBSEQUENT EVENTS
	On October 1, 2013 a director with significant industry experience, Timothy C. Tyson was appointed to the board of directors. Mr. Tyson was granted 20,000 options at an exercise price of $2.50 per share vesting over a 36 month period and an annual cash payment of $25,000 payable quarterly in arrears.
	Other than disclosed above, the Company has evaluated subsequent events through the date the unaudited consolidated financial statements were issued, and has concluded that no such events or transactions took place that would require disclosure herein.

Accounting_Policies_and_Estima1

Accounting Policies and Estimates (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies and Estimates [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).
	In the opinion of management, all adjustments necessary to fairly present the results for the interim periods presented have been made. All adjustments made are of a normal and recurring nature and no non-recurring adjustments have been made in the presentation of these interim financial statements.
	All amounts referred to in the notes to the financial statements are in United States Dollars ($) unless stated otherwise.
Consolidation	'
	Consolidation
	The consolidated financial statements include the financial statements of the Company and its subsidiaries in which it has a majority voting interest. Investments in affiliates are accounted for under the cost method of accounting, where appropriate. All significant inter-company accounts and transactions have been eliminated in the consolidated financial statements. The entities included in these consolidated financial statements are as follows:
	Caldera Pharmaceuticals, Inc. - Parent Company
	XRpro Corp. – Wholly owned subsidiary
Estimates	'
	Estimates
	The preparation of these financial statements in accordance with US GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to bad debts and recovery of long-lived assets. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the allowance for doubtful accounts, the useful life of plant and equipment and intangible assets, and assumptions used in assessing impairment of long-term assets and the assumptions used in determining percentage of completion on our long-term contracts.
Contingencies	'
	Contingencies
	Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.
	If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.
Fair value of financial instruments	'
	Fair value of financial instruments
	The Company adopted the guidance of Accounting Standards Codification (“ASC”) 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
	Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
	Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other then quoted prices that are observable, and inputs derived from or corroborated by observable market data.
	Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.
	The carrying amounts reported in the balance sheets for cash, accounts receivable, loans payable, accounts payable and accrued expenses approximate their fair market value based on the short-term maturity of these instruments. The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with the accounting guidance.
	ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.
Recent accounting pronouncements	'
	Recent accounting pronouncements
	The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and does not expect the future adoption of any such pronouncements to have a significant impact on the results of operations, financial condition or cash flow.
Reporting by segment	'
	Reporting by segment
	No segmental information is presented as the Company only has one significant reporting segment that is Government Revenues.
Intangible assets	'
	Intangible assets
	All of our intangible assets are subject to amortization . We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. Where intangibles are deemed to be impaired we recognize an impairment loss measured as the difference between the estimated fair value of the intangible and its book value.
	a)    License Agreements
	License agreements acquired by the Company are reported at acquisition value less accumulated amortization and impairments.
	b)    Amortization
	Amortization is reported in the income statement on a straight-line basis over the estimated useful life of the intangible assets, unless the useful life is indefinite. Amortizable intangible assets are amortized from the date that they are available for use. The estimated useful life of the license agreement is twenty years which is the term of the patent supporting the underlying license agreements
Plant and equipment	'
	Plant and equipment
	Plant and equipment is stated at cost less accumulated depreciation.  Depreciation is computed using straight-line method over the estimated useful lives of the assets. The estimated useful lives of the assets are as follows:
	Leasehold improvements	5 Years
	Laboratory equipment	7 Years
	Furniture and fixtures	10 Years
	Computer equipment	3 Years
	Motor vehicles (used)	2 Years
	The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition.
	We examine the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. We recognize an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.
Concentrations of credit risk	'
	Concentrations of credit risk
	The Company’s operations are carried out in the USA. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in the USA and by the general state of the economy. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, and rates and methods of taxation, among other things.
Concentration of major customers	'
	Concentration of major customers
	The Company currently derives substantially all of its revenues from Government research contracts and Government grants.
	These Government research contracts are primarily from two government agencies: The Department of Defense and the National Institutes of Health. The granting of research contracts from Government agencies is a competitive process and there is no certainty that we will be awarded future contracts, which may cause our revenue to fluctuate from year to year. Furthermore, Government grants are subject to audits by the granting agency. If such audits were to determine that expenditures of the grant funds did not meet the applicable criteria, these amounts could be subject to retroactive adjustment and refunded to the granting agency.
	Total revenues by customer type are as follows:
			Three months		Three months		Nine months		Nine months
			ended		ended		ended		ended
			September 30,		September 30,		September 30,		September 30,
			2013		2012		2013		2012
	National Institutes of Health		$	60,628	$	552,708	$	313,805	$	1,423,733
	Department of Defense			-		16,925		67,118		16,925
	Commercial customers			-		13,292		-		13,292
			$	60,628	$	582,925	$	380,923	$	1,453,950
Accounts receivable and other receivables	'
	Accounts receivable and other receivables
	We have a policy of reserving for uncollectible accounts based on our best estimate of the amount of probable credit losses in our existing accounts receivable. As a basis for accurately estimating the likelihood of collection of our accounts receivable, we consider a number of factors when determining reserves for uncollectable accounts. We believe that we use a reasonably reliable methodology to estimate the collectability of our accounts receivable. We review our allowances for doubtful accounts on a regular basis. We also consider whether the historical economic conditions are comparable to current economic conditions. If the financial condition of our customers or other parties that we have business relations with were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.
	The balance of the receivables provision as at September 30, 2013 and December 31, 2012 was $14,086 and $0, respectively. The amount charged to bad debt provision for the nine months ended September 30, 2013 and 2012 was $14,086 and $0, respectively.
Cash and cash equivalents	'
	Cash and cash equivalents
	For purposes of the statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents. The Company maintains cash and cash equivalents with two financial institutions in the USA.
Revenue recognition	'
	Revenue recognition
	Revenue sources consist of government grants, government contracts and commercial development contracts.
	We account for our long-term Firm Fixed Price Government contracts and grants associated with the delivery of research on drug candidates and the development of drug candidates using the percentage-of-completion accounting method. Under this method, revenue is recognized based on the extent of progress towards completion of the long-term contract.
	We generally use the cost-to-cost measure of progress for all of our long-term contracts, unless we believe another measure will produce a more reliable result. We believe that the cost-to-cost measure is the best and most reliable performance indicator of progress on our long-term contracts as all our contract estimates are based on costs that we expect to incur in performing our long-term contracts and we have not experienced any significant variations on estimated to actual costs to date. Under the cost-to-cost measure of progress, the extent of progress towards completion is based on the ratio of costs incurred-to-date to the total estimated costs at the completion of the long-term contract. Revenues, including estimated fees or profits are recorded as costs are incurred.
	When estimates of total costs to be incurred on a contract exceed total estimates of revenue to be earned, a provision for the entire loss on the contract is recorded in the period the loss is determined.
	To a much lesser extent, we enter into fixed fee commercial development contracts that are not associated with the delivery of feasible research on drug candidates and the development of drug candidates. Revenue under such contracts is generally recognized upon delivery or as the development is performed.
Sales and Marketing	'
	Sales and Marketing
	Sales and marketing expenses are minimal at present. These costs, if any, are expensed as incurred and included in Selling, general and administrative expenses. The Company expects to incur sales and marketing expenses in future periods to promote its services to drug discovery enterprises.
Research and Development	'
	Research and Development
	The remuneration of the Company’s research and development staff, materials used in internal research and development activities, and payments made to third parties in connection with collaborative research and development arrangements, are all expensed as incurred.  Where the Company makes a payment to a third party to acquire the right to use a product formula which has received regulatory approval, the payment is accounted for as the acquisition of a license or patent and is capitalized as an intangible asset and amortized over the shorter of the license period or the patent life.
	The amount expensed for unrecovered research costs, included in Selling, general and administrative expenses during the three months and the nine months ended September 30, 2013 was $46,944 and $122,347, respectively.
Patent Costs	'
	Patent Costs
	Legal costs in connection with approved patents and patent applications are expensed as incurred and classified as Selling, general and administrative expense in our consolidated statement of operations.
Share-Based Compensation	'
	Share-Based Compensation
	Share-based compensation cost is measured at the grant date, based on the estimated fair value of the award and is recognized as expense over the employee's requisite service period or vesting period on a straight-line basis. Share-based compensation expense recognized in the consolidated statements of operations for the nine months ended September 30, 2013 and 2012 is based on awards ultimately expected to vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. We have no awards with market or performance conditions.
Income Taxes	'
	Income Taxes
	The Company utilizes ASC 740, Accounting for Income Taxes, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
Net Loss per Share	'
	Net loss per Share
	Basic net loss per share is computed on the basis of the weighted average number of common stock outstanding during the period.
	Diluted net loss per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation.
	Dilution is computed by applying the treasury stock method for options and warrants. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.
	Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share).
Comprehensive income	'
	Comprehensive income
	Comprehensive income is defined as the change in equity of a company during a period from transactions and other events and circumstances excluding transactions resulting from investments from owners and distributions to owners. For the Company, comprehensive income for the periods presented includes net income/(loss).
Related parties	'
	Related parties
	Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company shall disclose all related party transactions. All transactions shall be recorded at fair value of the goods or services exchanged. Property purchased from a related party is recorded at the cost to the related party and any payment to or on behalf of the related party in excess of the cost is reflected as a distribution to related party.
Reclassification	'
	Reclassification
	Certain reclassifications have been made to conform the prior period data to the current presentation. These reclassifications have no effect on reported net loss.

Accounting_Policies_and_Estima2

Accounting Policies and Estimates (Tables)	9 Months Ended
	Sep. 30, 2013
Accounting Policies and Estimates [Abstract]	'
Summary of estimated useful lives of the assets	'
	Leasehold improvements	5 Years
	Laboratory equipment	7 Years
	Furniture and fixtures	10 Years
	Computer equipment	3 Years
	Motor vehicles (used)	2 Years
Summary of revenues by major customer type	'
			Three months		Three months		Nine months		Nine months
			ended		ended		ended		ended
			September 30,		September 30,		September 30,		September 30,
			2013		2012		2013		2012
	National Institutes of Health		$	60,628	$	552,708	$	313,805	$	1,423,733
	Department of Defense			-		16,925		67,118		16,925
	Commercial customers			-		13,292		-		13,292
			$	60,628	$	582,925	$	380,923	$	1,453,950

Intangible_Assets_Tables

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Intangible Assets [Abstract]	'
Summary of future annual minimum payments required under license agreement obligations	'
		Amount
	2014	$	50,000
	2015		50,000
	2016		50,000
	2017		50,000
	2018 and thereafter		250,000
	Total	$	450,000
Summary of licenses cost	'
		September 30,			December 31,
		2013			2012
		(Unaudited)
	Licenses, at cost	$	972,000		$	972,000
	Less: Accumulated amortization		(416,189	)		(377,426	)
		$	555,811		$	594,574
Summary of amortization expense for future years	'
		Amount
	Remainder of 2013	$	12,921
	2014		51,684
	2015		51,684
	2016		51,684
	2017 and thereafter		387,838
	Total	$	555,811

Plant_and_Equipment_Tables

Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Plant and Equipment [Abstract]	'
Components of Plant and equipment	'
		September 30,			December 31,
		2013			2012
		(Unaudited)
	Leasehold improvements	$	6,393		$	6,393
	Furniture and fittings		15,635			9,979
	Laboratory equipment		770,851			679,310
	Computer equipment		19,044			29,327
	Vehicles		17,658			17,658
	Total		829,581			742,667
	Accumulated depreciation		(418,502	)		(351,137	)
		$	411,079		$	391,530

Other_Payables_and_Accrued_Exp1

Other Payables and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2013
Other Payables and Accrued Expenses [Abstract]	'
Schedule of other payables and accrued expenses	'
		September 30,		December 31,
		2013		2012
		(Unaudited)
	Short-term portion
	Credit card liabilities	$	20,038	$	7,505
	Vacation and Sick Pay accrual		117,018		89,730
	Other payables		82,800		97,972
	Payroll liabilities		60,184		-
	Other		2,100		2,100
			282,140		197,307
	Long-term portion
	Other payables		82,800		160,000
		$	364,940	$	357,307
Schedule of amortization of other payables and accrued expenses	'
		Amount
	Within 1 year	$	82,800
	1 to 2 years		82,800
	Total	$	165,600

Loans_Payable_Tables

Loans Payable (Tables)	9 Months Ended
	Sep. 30, 2013
Loans Payable, Bridge Notes Payable and Notes Payable [Abstract]	'
Schedule of loans payable	'
		September 30,		December 31,
		2013		2012
		(Unaudited)
	Short term portion
	Los Alamos County project participation loan	$	32,459	$	31,270
	Los Alamos National Bank term loan		83,212		-
	Los Alamos National Bank revolving draw loan		-		168,827
	Los Alamos National Bank commercial loan		-		18,227
			115,671		218,324
	Long term portion
	Los Alamos County project participation loan		185,408		209,923
	Los Alamos National Bank term loan		184,898		-
	Los Alamos National Bank commercial loan		-		122,132
			370,306		332,055
	Total	$	485,977	$	550,379
Schedule of amortization of principal outstanding of loans payable	'
		Amount
	Within 1 year	$	115,671
	1 to 2 years		122,097
	2 to 3 years		128,954
	3 to 4 years		37,233
	Thereafter		82,022
	Total	$	485,977

Bridge_Notes_Payable_Tables

Bridge Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2013
Loans Payable, Bridge Notes Payable and Notes Payable [Abstract]	'
Schedule of Bridge Notes Payable	'
		September 30,		December 31,
		2013		2012
		(Unaudited)
	Bridge notes payable	$	-	$	250,890
	Unamortized bridge note discount		-		-16,935
		$	-	$	233,955

Derivative_Financial_Liability1

Derivative Financial Liability (Tables)	9 Months Ended
	Sep. 30, 2013
Derivative Financial Liability [Abstract]	'
Schedule of derivative financial liability fair value	'
		September 30,			December 31,
		2013			2012
		(Unaudited)
	Opening balance	$	17,539		$	-
	Derivative financial liability arising on bridge warrants with re-pricing terms		100,693			17,539
	Derivative financial liability arising on the issue of warrants relating to Series B shares		1,745,836			-
	Fair value adjustments		(388,093	)		-
		$	1,475,975		$	17,539
Summary of assumptions used in the Black-Scholes model	'
		Nine months ended
		September 30,
		2013
	Calculated stock price	$1.13- $1.27
	Risk-free interest rate	0.02% to 0.07%
	Expected life of warrants	5 Years
	Expected volatility of the underlying stock	100% -164%
	Expected dividend rate	0%

Warrants_Tables

Warrants (Tables)	9 Months Ended
	Sep. 30, 2013
Warrants [Abstract]	'
Summary of fair value assumptions of warrant	'
			Nine months ended			Year ended
			September 30,			December 31,
			2013			2012
	Calculated stock price			$1.13- $1.27			$0.55
	Risk-free interest rate		0.02% to 0.07%			0.01% to 0.15%
	Expected life of warrants		5 - 7 Years			5 Years
	Expected volatility of the underlying stock			100% - 164%			157%
	Expected dividend rate			0%			0%
Outstanding and exercisable warrants	'
				Warrants Outstanding						Warrants Exercisable
	Exercise Price			Number of	Weighted			Weighted Average		Number of		Weighted Average
				shares	average			Exercise Price		Shares		exercise Price
					remaining
					contractual
					years
	$	0.01		40,000		6.75					40,000
	$	2		15,000		3.07					15,000
	$	2.5		1,271,664		6.58					1,271,664
	$	2.75		286,800		6.75					286,800
	$	3		300,000		4.36					300,000
	$	5.7		384,407		2.69					384,407
				2,297,871		5.64		$	3.09		2,297,871	$	3.09

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Stock Based Compensation [Abstract]	'
Summary of weighted average assumptions	'
			Nine			Year ended
			months ended			December 31,
			September 30,			2012
			2013
	Calculated stock price		$1.13 to $1.27			$0.55
	Risk-free interest rate		0.02% to 0.07%			0.01% to 0.15%
	Expected life of options		5 Years			5 Years
	Expected volatility of the underlying stock		100 - 164%			128%
	Expected dividend rate		0%			0%
Summary of changes in options outstanding	'
							Exercise		Weighted
			Shares				price per		average
							share		exercise price
	Outstanding January 1, 2012			518,445			$	2.00 - 5.71	$	3.54
	Granted			47,000				0.20 - 5.71		1.97
	Forfeited/Cancelled			(59,291	)			1.10 - 5.71		5.71
	Exercised			-				-		-
	Outstanding December 31, 2012			506,154			$	0.20 - 5.71	$	3.14
	Granted			1,164,900				1.50 – 5.71		1.99
	Forfeited/Cancelled			(37,000	)			2.00 -5.71		3.93
	Exercised			-				-		-
	Outstanding September 30, 2013			1,634,054			$	0.20 - 5.71	$	2.31
Summary of information about stock options outstanding	'
					Options Outstanding						Options Exercisable
	Exercise Price				Number of		Weighted		Weighted		Number of		Weighted
					shares		average		Average		Shares		Average
							remaining		Exercise Price				exercise Price
							contractual
							years
	$	0.2			30,000			8.59				27,500
	$	1.1			220,000			7.42				220,000
	$	1.5			625,000			9.46				312,504
	$	2			15,000			2.12				15,000
	$	2.5			524,900			6.81				-
	$	5.71			219,154			5.1				219,154
					1,634,054			7.67	$	2.31		794,158	$	2.52

Net_Loss_Per_Common_Share_Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2013
Net Loss Per Common Share [Abstract]	'
Summary of dilutive shares exercise of outstanding stock instruments	'
		Nine months ended		Nine months ended
		September 30,		September 30,
		2013		2012
		(Shares)		(Shares)
	Options to purchase shares of common stock		1,634,054		477,967
	Series A convertible, redeemable preferred stock		105,000		341,607
	Series B convertible preferred stock		2,133,947		-
	Warrants		2,297,871		399,407
			6,170,872		1,218,981

Operating_Leases_Tables

Operating Leases (Tables)	9 Months Ended
	Sep. 30, 2013
Operating Leases [Abstract]	'
Summary of future annual minimum payments required under operating lease obligations	'
		Amount
	2013	$	60,404
	2014		92,214
		$	152,618

Accounting_Policies_and_Estima3

Accounting Policies and Estimates (Details)	9 Months Ended
	Sep. 30, 2013
Leasehold improvements [Member]	'
Summary of estimated useful life of assets	'
Estimated useful lives of the assets	'P5Y
Laboratory equipment [Member]	'
Summary of estimated useful life of assets	'
Estimated useful lives of the assets	'P7Y
Furniture and fixtures [Member]	'
Summary of estimated useful life of assets	'
Estimated useful lives of the assets	'P10Y
Computer equipment [Member]	'
Summary of estimated useful life of assets	'
Estimated useful lives of the assets	'P3Y
Motor vehicles (used) [Member]	'
Summary of estimated useful life of assets	'
Estimated useful lives of the assets	'P2Y

Accounting_Policies_and_Estima4

Accounting Policies and Estimates (Details 1) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Summary of total revenues by customer type	'	'	'	'
Sales	$60,628	$582,925	$380,923	$1,453,950
National Institutes of Health [Member]	'	'	'	'
Summary of total revenues by customer type	'	'	'	'
Sales	60,628	552,708	313,805	1,423,733
Department of Defense [Member]	'	'	'	'
Summary of total revenues by customer type	'	'	'	'
Sales	'	16,925	67,118	16,925
Commercial customers [Member]	'	'	'	'
Summary of total revenues by customer type	'	'	'	'
Sales	'	$13,292	'	$13,292

Accounting_Policies_and_Estima5

Accounting Policies and Estimates (Details Textual) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
		Segments
		Agency
Accounting Policies and Estimates (Textual)	'	'	'	'
Number of reportable segments	'	1	'	'
License agreement term	'	'20 years	'	'
Balance of bad debt provision	$14,086	$14,086	'	$0
Amount credited to bad debt provision	'	14,086	0	'
Number of financial institutions to maintain cash deposit	'	2	'	'
Research costs	$46,944	$122,347	'	'

Going_Concern_Details

Going Concern (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Going Concern (Textual)	'	'	'	'	'	'	'
Net loss	($540,108)	$215,808	($2,350,606)	($413,539)	'	'	'
Accumulated deficit	-11,357,932	'	-11,357,932	'	'	-6,967,435	'
Working capital deficiency	1,500,503	'	1,500,503	'	'	'	'
Non-cash derivative liability	$1,475,975	'	$1,475,975	'	$118,232	$17,539	'

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Sep. 30, 2013
Summary of future annual minimum payments required under license agreement obligations	'
2014	$50,000
2015	50,000
2016	50,000
2017	50,000
2018 and thereafter	250,000
Total	$450,000

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Summary of licenses cost	'	'
Licenses, at cost	$972,000	$972,000
Less: Accumulated amortization	-416,189	-377,426
Total	$555,811	$594,574

Intangible_Assets_Details_2

Intangible Assets (Details 2) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Summary of amortization expense for future periods	'	'
Remainder of 2013	$12,921	'
2014	51,684	'
2015	51,684	'
2016	51,684	'
2017 and thereafter	387,838	'
Total	$555,811	$594,574

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Intangible Assets (Textual)	'	'	'	'
License agreement term	'	'	'20 years	'
Shares issued to licensor of issued equity	'	'	3.00%	'
License agreement contains anti-dilutive clauses	'	'	'The agreement contains anti-dilutive clauses that will ensure that the Licensor maintains at least a 3% shareholding in the Company until the Company achieves equity financing of at least $20 million	'
Notice period of agreement termination	'	'	'90 days	'
Royalty to be paid to Licensor of net sale	'	'	2.00%	'
Minimum fee payment on license agreement increases per annum until December 31, 2022	'	'	$50,000	'
Amortization	$12,921	$12,921	$38,763	$38,763

Plant_and_Equipment_Details

Plant and Equipment (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Plant and equipment	'	'
Plant and equipment, gross	$829,581	$742,667
Accumulated depreciation	-418,502	-351,137
Plant and equipment, net	411,079	391,530
Leasehold improvements [Member]	'	'
Plant and equipment	'	'
Plant and equipment, gross	6,393	6,393
Furniture and fittings [Member]	'	'
Plant and equipment	'	'
Plant and equipment, gross	15,635	9,979
Laboratory equipment [Member]	'	'
Plant and equipment	'	'
Plant and equipment, gross	770,851	679,310
Computer equipment [Member]	'	'
Plant and equipment	'	'
Plant and equipment, gross	19,044	29,327
Vehicles [Member]	'	'
Plant and equipment	'	'
Plant and equipment, gross	$17,658	$17,658

Plant_and_Equipment_Details_Te

Plant and Equipment (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Plant and Equipment (Textual)	'	'	'	'
Depreciation	$30,704	$27,009	$86,353	$66,033

Other_Payables_and_Accrued_Exp2

Other Payables and Accrued Expenses (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Short term portion	'	'
Credit card liabilities	$20,038	$7,505
Vacation and Sick Pay accrual	117,018	89,730
Other payables	82,800	97,972
Payroll liabilities	60,184	'
Other	2,100	2,100
Other payables and accrued expenses, current	282,140	197,307
Long term portion	'	'
Other payables	82,800	160,000
Other payables and accrued expenses, net	$364,940	$357,307

Other_Payables_and_Accrued_Exp3

Other Payables and Accrued Expenses (Details 1) (USD $)	Sep. 30, 2013
Summary of amortization of other payables and accrued expenses	'
Within 1 year	$82,800
1 to 2 years	82,800
Total	$165,600

Loans_Payable_Details

Loans Payable (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Schedule of loans payable	'	'
Short term portion	$115,671	$218,324
Long term portion	370,306	332,055
Total	485,977	550,379
Los Alamos County project participation loan [Member]	'	'
Schedule of loans payable	'	'
Short term portion	32,459	31,270
Long term portion	185,408	209,923
Los Alamos National Bank term loan [Member]	'	'
Schedule of loans payable	'	'
Short term portion	83,212	'
Long term portion	184,898	'
Los Alamos National Bank revolving draw loan [Member]	'	'
Schedule of loans payable	'	'
Short term portion	'	168,827
Los Alamos National Bank commercial loan [Member]	'	'
Schedule of loans payable	'	'
Short term portion	'	18,227
Long term portion	'	$122,132

Loans_Payable_Details_1

Loans Payable (Details 1) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Schedule of amortization of principal outstanding on loans payable	'	'
Within 1 year	$115,671	'
1 to 2 years	122,097	'
2 to 3 years	128,954	'
3 to 4 years	37,233	'
Thereafter	82,022	'
Total	$485,977	$550,379

Loans_Payable_Details_Textual

Loans Payable (Details Textual) (USD $)

9 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

23-May-13

Sep. 16, 2013

Jun. 08, 2012

23-May-12

Sep. 30, 2013

Jul. 11, 2012

Sep. 16, 2013

Dec. 31, 2012

Sep. 16, 2013

Dec. 31, 2012

Sep. 21, 2006

Sep. 30, 2013

Dec. 31, 2007

Dec. 31, 2012

Sep. 16, 2013

Los Alamos National Bank [Member]

Los Alamos National Bank [Member]

Los Alamos National Bank [Member]

Los Alamos National Bank [Member]

Los Alamos National Bank [Member]

Los Alamos National Bank [Member]

Los Alamos National Bank [Member]

Los Alamos National Bank [Member]

Los Alamos National Bank [Member]

Los Alamos National Bank [Member]

Los Alamos County project participation loan [Member]

Los Alamos County project participation loan [Member]

Los Alamos County project participation loan [Member]

Los Alamos County project participation loan [Member]

Los Alamos National Bank Revolving Draw Line And Commercial Loan [Member]

May 23, 2012 [Member]

May 23, 2012 [Member]

June 8, 2012 [Member]

June 8, 2012 [Member]

Loans Payable (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum funding, loan amount

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,200,000

'

'

'

'

Term of loan

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

'13 years

'

'

'

'

Maximum funding loan amount for equipment

'

'

'

'

'

'

'

'

'

'

'

'

'

625,000

'

'

'

'

Payment term of loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'No repayments for 36 months with 120 equal monthly repayments commencing on September 21, 2009.

'

'

'

Interest rate on loan

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

Value of purchased assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

302,009

'

'

Equal monthly repayments, amount

'

'

'

'

'

'

'

'

'

'

'

'

'

3,547

'

'

'

'

Amount owed by company

485,977

'

550,379

'

'

'

'

'

'

'

168,827

'

140,359

'

217,867

'

241,193

'

Loan draw from bank

'

'

'

'

'

148,500

750,000

'

'

'

'

'

'

'

'

'

'

'

Loan amount reduced under the facility

'

'

'

167,943

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan amount repaid

'

'

'

'

'

'

'

'

'

168,472

'

126,501

'

'

'

'

'

26,886

Loan bears interest prime rate plus

'

'

'

'

2.00%

1.50%

1.50%

'

'

'

'

'

'

'

'

'

'

'

Loan bears interest floor rate

'

'

'

'

7.00%

6.00%

4.75%

'

'

'

'

'

'

'

'

'

'

'

Amount drew under credit agreement

'

'

'

'

'

'

50,000

'

118,000

'

'

'

'

'

'

'

'

'

New term loan amount

267,392

'

'

'

267,392

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt maturity date

'

'

'

'

16-Sep-16

8-Jun-19

'

23-Aug-13

'

'

'

'

'

'

'

'

'

'

Periodic payment

'

'

'

'

$8,256

$2,169

'

'

'

'

'

'

'

'

'

'

'

'

Frequency of Payments

'

'

'

'

'

'

'

'Repayable in 84 monthly installments

'

'

'

'

'

'

'

'

'

'

Repayable in 36 monthly installments

Bridge_Notes_Payable_Details

Bridge Notes Payable (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Schedule of Bridge notes payable	'	'
Bridge notes payable	'	$250,890
Unamortized bridge note discount	'	-16,935
Bridge notes payable, net of debt discount	'	$233,955

Bridge_Notes_Payable_Details_T

Bridge Notes Payable (Details Textual) (USD $)	9 Months Ended		0 Months Ended				3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Aug. 30, 2013	31-May-13	Apr. 19, 2013	Apr. 02, 2013	Sep. 30, 2013	Apr. 02, 2013	Sep. 30, 2013
			Bridge Loan [Member]	Bridge Loan [Member]	Bridge Loan [Member]	Bridge Loan [Member]	Bridge Loan [Member]	Bridge Loan [Member]	Bridge Loan [Member]
			Principal	Principal	Principal	Principal		Principal
Bridge Notes Payable (Textual)	'	'	'	'	'	'	'	'	'
Interest rate of note	'	'	'	'	'	10.00%	'	10.00%	'
Number of principals	'	'	3	3	6	9	'	9	'
Note principal amount	'	'	'	'	'	$500,000	'	$500,000	'
Bridge notes, description	'	'	'	'	'	'	'	'	'
								The Bridge Notes are issued as part of a unit that includes warrants to purchase 600 shares of the Company’s common stock for each $1,000 of Bridge Note principal, at an exercise price of $3.00 per share.
Class of Warrant or Right Exercise Price of Warrants or Rights	'	'	'	'	'	3	'	'	'
Default interest rate per annum	'	'	'	'	'	15.00%	'	'	'
Debt maturity date	'	'	'	'	'	31-Dec-13	'	'	'
Conversion of note, description	'	'	'	'	'	'	'	'	'The Bridge Notes together with any interest due on the Bridge Notes will, at the option of the note holder, convert into securities of the Company's subsequent financing. The Bridge Note holder also has the option to convert some or all of the principal and interest due on this note into shares of the Company's common stock at a conversion price of $2.50 per share, unless a default has occurred and is continuing, at which instance the conversion price during the default period shall be $1.50 per share.
Principal amount of notes converted into series B preferred units	'	'	'	'	375,000	'	'	'	'
Accrued and unpaid interest converted into series B preferred units	'	'	'	'	9,160	'	'	'	'
Number of series B preferred units issued upon conversion of debt	'	'	'	'	153,664	'	'	'	'
Conversion price	'	'	'	'	$2.50	'	'	'	'
Description of series B preferred units issued	'	'	'	'	'Each unit consist of one share of series B preferred stock and one seven-year warrant exercisable at a price of $2.50 per share, which price is subject to anti-dilution protection.	'	'	'	'
Principal amount of debt repaid	'	'	25,000	100,000	'	'	'	'	'
Accrued and unpaid interest on notes repaid	'	'	1,073	1,541	'	'	'	'	'
Discount relating to fair value of warrants issued	'	'	'	'	'	'	118,232	'	118,232
Immediate amortization of debt discount	'	'	'	'	'	'	'	'	90,487
Bridge note discount amortized	$117,629	'	'	'	'	'	$1,096	'	'

Notes_Payable_Details

Notes Payable (Details) (Notes payable [Member], USD $)	0 Months Ended
	Mar. 25, 2013
Notes payable [Member]	'
Notes Payable (Textual)	'
Note principal amount	$100,000
Interest rate of note	10.00%
Debt maturity date	4-Apr-13

Derivative_Financial_Liability2

Derivative Financial Liability (Details) (USD $)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012
Schedule of derivative financial liability fair value	'	'	'
Opening balance	$118,232	$17,539	'
Derivative financial liability arising on bridge warrants with re-pricing terms	'	100,693	17,539
Derivative financial liability arising on the issue of warrants relating to Series B shares	1,745,836	1,745,836	'
Fair value adjustments	'	-388,093	'
Ending Balance	$1,475,975	$1,475,975	$17,539

Derivative_Financial_Liability3

Derivative Financial Liability (Details 1) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Summary of assumptions used in the Black-Scholes model	'	'
Calculated stock price	'	$0.55
Expected life of warrants	'5 years	'
Expected dividend rate	0.00%	'
Minimum [Member]	'	'
Summary of assumptions used in the Black-Scholes model	'	'
Calculated stock price	$1.13	'
Risk-free interest rate	0.02%	'
Expected volatility of the underlying stock	100.00%	'
Maximum [Member]	'	'
Summary of assumptions used in the Black-Scholes model	'	'
Calculated stock price	$1.27	'
Risk-free interest rate	0.07%	'
Expected volatility of the underlying stock	164.00%	'

Derivative_Financial_Liability4

Derivative Financial Liability (Details Textual) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Jun. 30, 2013	Dec. 31, 2011
Derivative Financial Liability (Textual)	'	'	'	'	'	'	'
Derivative financial liability	$1,475,975	'	$1,475,975	'	$17,539	$118,232	'
Derivative financial liability arising on the issue of warrants relating to Series B shares	1,745,836	'	1,745,836	'	'	'	'
Change in fair value of derivative liabilities	$536,665	'	$388,094	'	'	'	'

Preferred_Stock_Details

Preferred Stock (Details) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

20-May-13

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Apr. 19, 2013

Aug. 30, 2013

31-May-13

Apr. 02, 2013

Apr. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Apr. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Placement agent [Member]

Placement agent [Member]

New Investor

Bridge Loan [Member]

Bridge Loan [Member]

Bridge Loan [Member]

Bridge Loan [Member]

Series A convertible redeemable preferred shares [Member]

Series A convertible redeemable preferred shares [Member]

Series A convertible redeemable preferred shares [Member]

Series B convertible preferred stock [Member]

Series B convertible preferred stock [Member]

Series B convertible preferred stock [Member]

Series B convertible preferred stock [Member]

Principal

Principal

Principal

Principal

Preferred Stock (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

'

$0.00

$0.00

$0.00

Preferred stock, shares designated

10,000,000

10,000,000

10,000,000

'

'

'

'

'

'

'

'

'

'

400,000

'

'

3,000,000

3,000,000

3,000,000

Number of preferred stock shares undesignated

6,600,000

6,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, dividend rate - Series A

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

105,000

341,607

'

2,133,947

2,133,947

'

Convertible redeemable preferred stock, description

'

'The articles of Incorporation were amended on April 10, 2012 to change the designation of all of the 10,000,000 preferred shares of $0.001 each, from Series A 8% convertible redeemable preferred shares to 400,000 Series A 8% convertible redeemable preferred shares of $0.001 each

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of conversion of preferred stock series B to series A

'

'The number of series B preferred shares issued was derived at by dividing the total dollar investment made in the Company by each Series A stockholder by $2.50.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock Exchanged

'

'

'

'

'

'

'

'

'

'

'

'

341,607

'

'

778,860

'

'

'

Series B preferred stock issued as dividends to Series A stockholders

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

83,423

'

'

'

Preferred stock, shares outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

105,000

341,607

'

2,133,947

2,133,947

'

Investment from Stockholder

'

'

'

'

'

'

'

'

'

'

'

'

'

$210,000

'

'

'

'

'

Carrying value series A stock

'

'

'

'

'

'

'

'

'

'

'

'

'

133,350

'

'

'

'

'

Series A exchange price per share

'

'

'

'

'

'

'

'

'

'

'

'

$2.50

'

'

$2.50

'

'

'

Principal amount of notes converted into series B preferred units

'

'

'

'

'

'

'

'

375,000

'

'

'

'

'

'

'

'

'

'

Number of principals

'

'

'

'

'

'

'

'

6

3

3

9

'

'

'

'

'

'

'

Accrued and unpaid interest converted into series B preferred units

'

'

'

'

'

'

'

'

9,160

'

'

'

'

'

'

'

'

'

'

Number of series B preferred units issued upon conversion of debt

'

'

'

'

'

'

'

'

153,664

'

'

'

'

'

'

'

'

'

'

Conversion price

'

'

'

'

'

'

'

'

$2.50

'

'

'

'

'

'

'

'

'

'

Warrant exercise price - Series B

2.5

2.5

'

'

'

0.01

2.75

2.5

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

'

'

'

'

40,000

286,800

1,118,000

'

'

'

'

'

'

'

'

'

'

'

Expected life of warrants

'

'

'5 years

'

'

'7 years

'7 years

'7 years

'7 years

'

'

'

'

'

'

'

'

'

'

Net proceed from series B Convertible Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31,150

2,509,700

'

Placement agent fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,400

1,400

'

Preferred stock dividend rate - Series B

'

'Series B Stock accrue dividends at the rate per annum equal to (i) 8% of the sum of (x) the Stated Value and (y) the amount of accrued and unpaid dividends payable, out of funds legally available for payment, on January 31st of each year, if paid in cash, or (ii) 10% of the sum of (x) the Stated Value and (y) the amount of accrued and unpaid dividends payable, out of funds legally available for payment, on January 31st of each year, if paid in shares of Common Stock, based upon a price of $2.50 per share of Common Stock.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends payable - Series A Stock

242,374

242,374

156,873

'

117,373

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends payable - Series B Stock

224,786

224,786

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock exchanged for series A shares

'

'

'

105,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred shares exchanged for common stock, value

'

'

'

133,350

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average price of common stock, Minimum per share

'

$10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant expiration period - Series A

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant expiration period - Series B

'

'7 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum litigation proceedings, net

'

$3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, redeemable option, description

'

'Redeem the Series A Stock at a price equal to 130% of the initial investment in the Company by the stockholder at any time after giving the investors notice and allowing them to exercise their conversion rights into common stock 30 days after notice has been received.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liquidation rights of preferred stock, per share - Series A

$5.70

$5.70

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liquidation rights of preferred stock, per share - Series B

$2.50

$2.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum purchase price of common stock

'

$2.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum common stock under equity incentive plans

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Series B convertible preferred stock voting rights, Description

'

'Each holder of Series B Stock is entitled to cast the number of votes equal to two times the number of shares of Common Stock into which such shares of Series B Stock could be converted at the record date for determining stockholders entitled to vote at the meeting.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common_Stock_Details

Common Stock (Details) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	20-May-13
Common Stock (Textual)	'	'	'	'
Common stock, shares authorized	50,000,000	'	50,000,000	'
Common stock, par value	$0.00	'	$0.00	'
Common stock, shares issued	4,851,270	'	4,956,270	'
Common stock, shares outstanding	4,197,270	'	4,302,270	'
Common stock issued in lieu of cash for preferred stock dividend, shares	'	'	10,650	'
Share price	'	'	$0.55	'
Common stock issued in lieu of preferred stock dividends	'	$60,705	$60,705	'
Common stock exchanged for series A shares	'	'	'	105,000

Warrants_Details

Warrants (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Summary of fair value assumptions of warrant	'	'
Calculated stock price	'	0.55
Minimum [Member]	'	'
Summary of fair value assumptions of warrant	'	'
Calculated stock price	1.13	'
Maximum [Member]	'	'
Summary of fair value assumptions of warrant	'	'
Calculated stock price	1.27	'
Warrants [Member]	'	'
Summary of fair value assumptions of warrant	'	'
Risk-free interest rate, Minimum	0.02%	0.01%
Risk-free interest rate, Maximum	0.07%	0.15%
Expected life of warrants	'	'5 years
Expected volatility of the underlying stock	'	157.00%
Expected dividend rate	0.00%	0.00%
Warrants [Member] | Minimum [Member]	'	'
Summary of fair value assumptions of warrant	'	'
Calculated stock price	1.13	'
Expected life of warrants	'5 years	'
Expected volatility of the underlying stock	100.00%	'
Warrants [Member] | Maximum [Member]	'	'
Summary of fair value assumptions of warrant	'	'
Calculated stock price	1.27	'
Expected life of warrants	'7 years	'
Expected volatility of the underlying stock	164.00%	'

Warrants_Details_1

Warrants (Details 1) (Warrant [Member], USD $)	9 Months Ended
	Sep. 30, 2013
Outstanding And Exercisable Warrants [Abstract]	'
Number of shares, warrants outstanding	2,297,871
Weighted average remaining contractual years, warants outstanding	'5 years 7 months 21 days
Weighted average exercise price, warrants outstanding	$3.09
Number of shares, warrants exercisable	2,297,871
Weighted average exercise price, warrants exercisable	$3.09
0.01 [Member]	'
Outstanding And Exercisable Warrants [Abstract]	'
Exercise price	$0.01
Number of shares, warrants outstanding	40,000
Weighted average remaining contractual years, warants outstanding	'6 years 9 months
Weighted average exercise price, warrants outstanding	'
Number of shares, warrants exercisable	40,000
2.00 [Member]	'
Outstanding And Exercisable Warrants [Abstract]	'
Exercise price	$2
Number of shares, warrants outstanding	15,000
Weighted average remaining contractual years, warants outstanding	'3 years 26 days
Weighted average exercise price, warrants outstanding	'
Number of shares, warrants exercisable	15,000
2.50 [Member]	'
Outstanding And Exercisable Warrants [Abstract]	'
Exercise price	$2.50
Number of shares, warrants outstanding	1,271,664
Weighted average remaining contractual years, warants outstanding	'6 years 6 months 29 days
Weighted average exercise price, warrants outstanding	'
Number of shares, warrants exercisable	1,271,664
2.75 [Member]	'
Outstanding And Exercisable Warrants [Abstract]	'
Exercise price	$2.75
Number of shares, warrants outstanding	286,800
Weighted average remaining contractual years, warants outstanding	'6 years 9 months
Weighted average exercise price, warrants outstanding	'
Number of shares, warrants exercisable	286,800
3.00 [Member]	'
Outstanding And Exercisable Warrants [Abstract]	'
Exercise price	$3
Number of shares, warrants outstanding	300,000
Weighted average remaining contractual years, warants outstanding	'4 years 4 months 10 days
Weighted average exercise price, warrants outstanding	'
Number of shares, warrants exercisable	300,000
5.70 [Member]	'
Outstanding And Exercisable Warrants [Abstract]	'
Exercise price	$5.70
Number of shares, warrants outstanding	384,407
Weighted average remaining contractual years, warants outstanding	'2 years 8 months 9 days
Weighted average exercise price, warrants outstanding	'
Number of shares, warrants exercisable	384,407

Warrants_Details_Textual

Warrants (Details Textual) (USD $)

3 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Apr. 04, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Apr. 19, 2013

Bridge Note holders [Member]

Bridge Note holders [Member]

Bridge Note holders [Member]

Qualified investors [Member]

Placement agent [Member]

Placement agent [Member]

Investor [Member]

Bridge Loan [Member]

Warrants (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

'

'

'

'

153,664

300,000

300,000

1,118,000

40,000

286,800

10,088

'

Exercise price of warrant

'

'

'

'

'

2.5

3

3

2.5

0.01

2.75

5.7

'

Additional warrants for purchase of common stock

'

'

'

'

'

'

300,000

300,000

'

'

'

'

'

Expected life of warrants

'

'

'

'

'5 years

'7 years

'5 years

'5 years

'7 years

'7 years

'7 years

'5 years

'7 years

Convertible preferred stock and common stock purchase warrants issued to Series "A" preferred stockholders

'

'

'

'

$10,088

'

'

'

'

'

'

'

'

Fair market value of warrants

1,745,836

'

1,745,836

'

'

'

'

'

'

'

'

'

'

Warrants issued in connection with preferred stock offering

14,000

'

1,271,664

'

'

'

'

'

'

'

'

'

'

Warrants issued to placement agent and advisory fees

1,400

'

326,800

'

'

'

'

'

'

'

'

'

'

Discount applied to Bridge notes relating to warrants issued

'

'

100,693

'

17,539

'

'

'

'

'

'

'

'

Deemed preferred stock dividend

$16,925

'

$1,745,837

$2,857

$2,857

'

'

'

'

'

'

'

'

Stock_Based_Compensation_Detai

Stock Based Compensation (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Summary of weighted average assumptions	'	'
Calculated stock price	'	$0.55
Minimum [Member]	'	'
Summary of weighted average assumptions	'	'
Calculated stock price	$1.13	'
Maximum [Member]	'	'
Summary of weighted average assumptions	'	'
Calculated stock price	$1.27	'
Stock Options [Member]	'	'
Summary of weighted average assumptions	'	'
Calculated stock price	'	$0.55
Risk-free interest rate, Minimum	0.02%	0.01%
Risk-free interest rate, Maximum	0.07%	0.15%
Expected life of options	'5 years	'5 years
Expected volatility of the underlying stock	'	128.00%
Expected dividend rate	0.00%	0.00%
Stock Options [Member] | Minimum [Member]	'	'
Summary of weighted average assumptions	'	'
Calculated stock price	$1.13	'
Expected volatility of the underlying stock	100.00%	'
Stock Options [Member] | Maximum [Member]	'	'
Summary of weighted average assumptions	'	'
Calculated stock price	$1.27	'
Expected volatility of the underlying stock	164.00%	'

Stock_Based_Compensation_Detai1

Stock Based Compensation (Details 1) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Summary of changes in options outstanding	'	'
Shares, Granted	514,900	'
Shares, Forfeited/Cancelled	-37,000	-59,291
Weighted Average Exercise Price, Exercised	'	'
Stock Options [Member]	'	'
Summary of changes in options outstanding	'	'
Shares Outstanding, Beginning balance	506,154	518,445
Shares, Granted	1,164,900	47,000
Shares, Forfeited/Cancelled	-37,000	-59,291
Shares, Exercised	'	'
Shares Outstanding, Ending balance	1,634,054	506,154
Weighted Average Exercise Price, Beginning Balance	3.14	$3.54
Weighted Average Exercise Price, Granted	1.99	$1.97
Weighted Average Exercise Price, Forfeited/Cancelled	3.93	$5.71
Weighted Average Exercise Price, Exercised	'	'
Weighted Average Exercise Price, Ending Balance	2.31	$3.14
Stock Options [Member] | Minimum [Member]	'	'
Summary of changes in options outstanding	'	'
Exercise price per share, Beginning balance	0.2	$2
Exercise price per share, Granted	1.5	$0.20
Exercise price per share Forfeited/Cancelled	2	$1.10
Exercise price per share, Exercised	'	'
Exercise price per share, Ending balance	0.2	$0.20
Stock Options [Member] | Maximum [Member]	'	'
Summary of changes in options outstanding	'	'
Exercise price per share, Beginning balance	5.71	$5.71
Exercise price per share, Granted	5.71	$5.71
Exercise price per share Forfeited/Cancelled	5.71	$5.71
Exercise price per share, Exercised	'	'
Exercise price per share, Ending balance	5.71	$5.71

Stock_Based_Compensation_Detai2

Stock Based Compensation (Details 2) (Stock Options [Member], USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of information about stock options outstanding	'	'	'
Number of shares, Options Outstanding	1,634,054	506,154	518,445
Weighted average remaining contractual years, Option outstanding	'7 years 8 months 1 day	'	'
Weighted Average Exercise Price, Option Outstanding	$2.31	$3.14	$3.54
Number of Shares, Option exercisable	794,158	'	'
Weighted Average exercise Price, Options Exercisable	$2.52	'	'
$0.20 [Member]	'	'	'
Summary of information about stock options outstanding	'	'	'
Exercise Price, Options Outstanding	$0.20	'	'
Number of shares, Options Outstanding	30,000	'	'
Weighted average remaining contractual years, Option outstanding	'8 years 7 months 2 days	'	'
Weighted Average Exercise Price, Option Outstanding	'	'	'
Number of Shares, Option exercisable	27,500	'	'
Weighted Average exercise Price, Options Exercisable	'	'	'
$1.10 [Member]	'	'	'
Summary of information about stock options outstanding	'	'	'
Exercise Price, Options Outstanding	$1.10	'	'
Number of shares, Options Outstanding	220,000	'	'
Weighted average remaining contractual years, Option outstanding	'7 years 5 months 1 day	'	'
Weighted Average Exercise Price, Option Outstanding	'	'	'
Number of Shares, Option exercisable	220,000	'	'
Weighted Average exercise Price, Options Exercisable	'	'	'
$ 1.50 [Member]	'	'	'
Summary of information about stock options outstanding	'	'	'
Exercise Price, Options Outstanding	$1.50	'	'
Number of shares, Options Outstanding	625,000	'	'
Weighted average remaining contractual years, Option outstanding	'9 years 5 months 16 days	'	'
Weighted Average Exercise Price, Option Outstanding	'	'	'
Number of Shares, Option exercisable	312,504	'	'
Weighted Average exercise Price, Options Exercisable	'	'	'
$2.00 [Member]	'	'	'
Summary of information about stock options outstanding	'	'	'
Exercise Price, Options Outstanding	$2	'	'
Number of shares, Options Outstanding	15,000	'	'
Weighted average remaining contractual years, Option outstanding	'2 years 1 month 13 days	'	'
Weighted Average Exercise Price, Option Outstanding	'	'	'
Number of Shares, Option exercisable	15,000	'	'
Weighted Average exercise Price, Options Exercisable	'	'	'
$2.50 [Member]	'	'	'
Summary of information about stock options outstanding	'	'	'
Exercise Price, Options Outstanding	$2.50	'	'
Number of shares, Options Outstanding	524,900	'	'
Weighted average remaining contractual years, Option outstanding	'6 years 9 months 22 days	'	'
Weighted Average Exercise Price, Option Outstanding	'	'	'
Number of Shares, Option exercisable	'	'	'
Weighted Average exercise Price, Options Exercisable	'	'	'
$5.71 [Member]	'	'	'
Summary of information about stock options outstanding	'	'	'
Exercise Price, Options Outstanding	$5.71	'	'
Number of shares, Options Outstanding	219,154	'	'
Weighted average remaining contractual years, Option outstanding	'5 years 1 month 6 days	'	'
Weighted Average Exercise Price, Option Outstanding	'	'	'
Number of Shares, Option exercisable	219,154	'	'
Weighted Average exercise Price, Options Exercisable	'	'	'

Stock_Based_Compensation_Detai3

Stock Based Compensation (Details Textual) (USD $)	1 Months Ended	9 Months Ended		12 Months Ended	9 Months Ended	0 Months Ended
	Oct. 31, 2005	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013	Oct. 01, 2013
					Board of directors [Member]	Board of directors [Member]
						Subsequent Event [Member]
Stock Based Compensation (Textual)	'	'	'	'	'	'
Shares of common stock for issuance upon exercise of grants under plan	3,000,000	'	'	'	'	'
Share-based payment award, award vesting period	'	'Either immediately or over a period of up to two years, and expire 1 year to 10 years from the grant date.	'	'	'	'
Shares available for future grant under the Incentive Plan	'	1,365,946	'	'	'	'
Stock based compensation payments	'	$441,566	$48,852	'	'	'
Share based payment award minimum expiry period	'1 year	'	'	'	'	'
Share based payment award maximum expiry period	'10 years	'	'	'	'	'
Short term maturities period	'3 months	'	'	'	'	'
Options forfeited & cancelled	'	37,000	'	59,291	'	'
Stock options outstanding intrinsic value	'	33,325	'	0	'	'
Weighted-average grant-date fair values of options granted	'	1,282,147	'	17,068	'	'
Weighted-average grant-date fair values of options granted per share	'	$1.10	'	$0.46	'	'
Unvested options to purchase common stock	'	839,896	'	'	'	'
Expected unrecognized compensation cost	'	$833,356	'	'	'	'
Expected to be recognized over period	'	'45 months	'	'	'	'
Option granted	'	514,900	'	'	20,000	20,000

Net_Loss_Per_Common_Share_Deta

Net Loss Per Common Share (Details)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Summary of dilutive shares exercise of outstanding stock instruments	'	'
Dilutive shares pursuant to the exercise of outstanding stock instruments	6,170,872	1,218,981
Options to purchase shares of common stock [Member]	'	'
Summary of dilutive shares exercise of outstanding stock instruments	'	'
Dilutive shares pursuant to the exercise of outstanding stock instruments	1,634,054	477,967
Series A convertible, redeemable preferred stock [Member]	'	'
Summary of dilutive shares exercise of outstanding stock instruments	'	'
Dilutive shares pursuant to the exercise of outstanding stock instruments	105,000	341,607
Series B convertible preferred stock [Member]	'	'
Summary of dilutive shares exercise of outstanding stock instruments	'	'
Dilutive shares pursuant to the exercise of outstanding stock instruments	2,133,947	'
Warrants [Member]	'	'
Summary of dilutive shares exercise of outstanding stock instruments	'	'
Dilutive shares pursuant to the exercise of outstanding stock instruments	2,297,871	399,407

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	9 Months Ended			1 Months Ended	0 Months Ended		0 Months Ended	9 Months Ended
	Sep. 30, 2013	Oct. 01, 2013	Dec. 31, 2012	Jul. 31, 2013	Apr. 30, 2013	Apr. 30, 2013	Mar. 15, 2013	Sep. 30, 2013
				Employment Agreement [Member]	Exchange Agreement [Member]	Exchange Agreement [Member]	Chief Executive Officer [Member]	Chief Executive Officer [Member]
				Mr.Gary Altman [Member]	Series A Preferred Stock	Series B Preferred Stock	Employment Agreement [Member]	Employment Agreement [Member]
Related Party Transactions (Textual)	'	'	'	'	'	'	'	'
Term of employment agreement	'	'	'	'4 years	'	'	'5 years	'
Annual base salary under agreement	'	'	'	$300,000	'	'	'	'
Increased annual base salary	'	'	'	325,000	'	'	'	'
Options to purchase shares, grants	514,900	'	'	'	'	'	185,000	'
Exercise price	'	'	'	'	'	'	$1.50	'
Description of vesting of option	'	'	'	'Options will vest as to 64,360 six months after the effective date of the contract and the remaining options will vest equally over the following forty-two month period.	'	'	'	'Options will vest pro rata, on a monthly basis over twelve months, with 15,417 vesting each month commencing April 1, 2013.
Number of shares vested or expected to vest monthly	'	'	'	'	'	'	15,417	'
Shares convertible under agreement	'	'	'	'	25,035	'	'	'
Convertible preferred stock, shares issued upon conversion	'	'	'	'	'	63,201	'	'
Accrued and unpaid dividend on preferred stock	'	'	'	'	$15,300	'	'	'
Exercise price of warrant	2.5	2.5	'	'	'	'	'	'
Majority of common shares owned by Dr. Benjamin Warner	76.00%	'	74.10%	'	'	'	'	'

Operating_Leases_Details

Operating Leases (Details) (USD $)	Sep. 30, 2013
Summary of future annual minimum payments required under operating lease obligations	'
2013	$60,404
2014	92,214
Future Minimum Payments due under operating lease obligations	$152,618

Operating_Leases_Details_Textu

Operating Leases (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Laboratory and office lease [Member]	'	'
Operating Leases (Textual)	'	'
Area of leased office space (in square feet)	2,813	'
Term of lease	'12 months	'
Lease expiration date	31-May-14	'
Monthly rent expense under lease agreement	$15,118	'
Rental expense	61,795	'
Corporate apartment lease [Member]	'	'
Operating Leases (Textual)	'	'
Term of lease	'12 months	'
Lease expiration date	3-Jun-14	'
Monthly rent expense under lease agreement	3,325	'
Rental expense	14,243	'
Office lease [Member]	'	'
Operating Leases (Textual)	'	'
Lease expiration period	'October 2013.	'
Monthly rent expense under lease agreement	5,075	'
Rental expense	$45,678	$44,348

Litigation_Details

Litigation (Details) (USD $)	9 Months Ended		0 Months Ended	1 Months Ended					9 Months Ended	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Oct. 04, 2013	Sep. 30, 2011	Oct. 31, 2010	Dec. 31, 2007	20-May-13	Oct. 31, 2008	Sep. 30, 2013	Dec. 31, 2012
			Subsequent Event [Member]	LANS [Member]	LANS [Member]	LANS [Member]	Joel Bellows [Member]	Joel Bellows [Member]	Joel Bellows [Member]	Joel Bellows [Member]
Litigation (Textual)	'	'	'	'	'	'	'	'	'	'
Relief expected from litigation settlement	'	'	'	$600,000,000	$600,000,000	$600,000,000	'	'	'	'
Aggregate investment amount in common stock claimed by Bastanipour and Bellows	'	'	'	'	'	'	'	218,000	'	'
Terms of settlement agreement	'In February 2013 a settlement agreement was entered into between the Company, Joel Bellows and Peter Baltrus, with respect to the October 2008 and December 2010 suits, which requires the exchange of 105,000 common shares for 105,000 shares of Series A Stock or Series B Stock and a cash payment of $240,000, together with interest thereon at 6% per annum, over a three-year period.	'	'	'	'	'	'	'	'	'
Accrual expense	'	'	'	'	'	'	'	'	'	257,972
Cash paid for litigation settlement	'	'	30,000	'	'	'	'	'	'	'
Series A Stock issued in exchange of litigation settlement	'	'	'	'	'	'	105,000	'	'	'
Legal settlement expense	-115,273	'	'	'	'	'	'	'	115,273	'
Common stock exchanged under settlement agreement	'	'	'	'	'	'	105,000	'	'	'
Litigation and contigency fees	$2,177,463	'	'	'	'	'	'	'	'	'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	9 Months Ended			0 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Oct. 01, 2013
		Board of Directors Chairman [Member]	Board of directors [Member]	Subsequent Event [Member]
				Board of directors [Member]
Subsequent Events (Textual)	'	'	'	'
Options to purchase shares, grants	514,900	20,000	20,000	20,000
Exercise price	'	'	'	$2.50
Annual cash payment	'	'	'	$25,000